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Peucedanum japonicum Thunberg, belongs to Umbelliferae family, was 
distributed in southern and eastern Asian countries. Its roots were traditionally used 
as a medicine for cold and neuralgic diseases in Korea and Taiwan.  
It was reported that the roots of this plant contained coumarins, chromones, 
polyacetylenes, sugar alcohols, and steroid glycosides. Pharmacological researches 
revealed that P. japonicum roots showed antioxidative, anti-inflammatory, antifungal 
activity and cytotoxic effect against lymphocytic leukaemia.  
In this study, sixteen new angular dihydropyranocoumarins (1-16) and three 
new angular monohydromonohydroxyfuranocoumarins (41-43) were isolated along 
with forty-five known compounds from the n-hexane and CHCl3 fractions of the P. 
japonicum roots. The known compounds were characterized as angular 
dihydropyranocoumarins (17-40), linear furanocoumarins (44-47), an angular 
dihydrofuranocoumarin (48), a linear dihydropyranocoumarin (49), simple 
coumarins (50-58), a chromone (59), ferulic acid derivatives (60-61), a lignan (62), 
a phenylpropanoid (63), and an indole alkaloid (64). 
Isolated angular dihydropyranocoumarins (khellactones) included monoacyl- 
and diacyl-type khellactone esters. In the case of monoacylkhellactones, the absolute 
configuration was easily determined by the Mosher method. However, the absolute 
configuration of diacyl khellactone esters was difficult to assign due to the absence 
of free hydroxyl group. Therefore, partial alkaline hydrolysis prior to MTPA 
derivatization and X-ray diffraction analysis were applied to determine the absolute 
configurations at 3’- and 4’-positions. Because the success of partial hydrolysis and 
single crystallization was very difficult, ECD spectroscopy was suggested to confirm 
the absolute configuration of most of the compounds. 
Interestingly, a few enantiomers were discovered and isolated by enantio-
selective column. Enantiomers were usually detected and isolated using chiral 
column. However, RP-HPLC analysis with MTPA reaction products could be 




chiral-selective columns. In the case of cis-monoacylkhellactones, the 
interconversion of substituents at 3’- and 4’-position was observed. The major MS 
fragment peak of khellactone esters was detected without a C-4’ substituent. Thus, 
the position of substituents at 3’ and 4’ could be determined by MS fragmentation 
analysis without HMBC measurement. 
The NO production inhibitory activity of isolated compounds were tested using 
Griess assay in LPS-induced RAW264.7 cells. As a result, 1, 3-6, 22, 31, and 36-38 
showed significant activity without cytotoxicity. The isobutyryl, senecioyl, 2-
methylbutyryl, and isovaleryl moieties at 3’ position played more important role than 
the acetyl and angeloyl groups. 
In conclusion, the absolute configuration of isolated compounds were assigned 
by various methods. Those methods will become useful guide to solve similar 
structures. The isolated compounds which significantly inhibited NO production 
were suggested as anti-inflammatory candidates from natural resources. 
 
Keyword : Peucedanum japonicum, angular dihydropyranocoumarins, khellactone 
esters, partial hydrolysis, X-ray crystallography, and Circular dichroism (CD) 
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Chapter 1. Introduction 
 
1.1. Study Background 
 
1.1.1. The genus Peucedanum and Peucedanum japonicum Thunberg 
 
The genus Peucedanum belongs to Umbelliferae (Apiaceae) and there are more 
than 120 species, which are distributed in Europe, Asia, Africa, and North America. 
The major constituents of most Peucedanum plants are coumarins and essential oils 
like most plants of the Umbelliferae family and they are important for their 
pharmacological activities of Peucedanum species (Sarkhail 2014). Among the 
Peucedanum species, the most frequently studied species are P. praeruptorum, P. 
japonicum, and P. decursivum.  
Peucedanum japonicum Thunberg is widely distributed in southern and eastern 
Asian countries. The roots of P. japonicum are cone or spindle shaped, are 5-15 cm 
long, and have 2-4 lateral roots (Whang et al. 2001). In Korea, Japan, China, and 
Taiwan, they have been traditionally used for cold and headache (Gan 1965; Bae 
2001). Pharmacological studies reported that P. japonicum roots had antioxidative, 
anti-inflammatory (Kim et al. 2009; Choi et al. 1999), antifungal (Bae 2002), 
hypoglycemic (Lee et al. 2004), and antiplatelet aggregation activities (Hsiao et al. 
1998; Chen et al. 1996). In addition, this plant also had vasorelaxant effect (Lee et 
al. 2002), MAO inhibitory activity (Huong et al. 1999), topoisomerase I inhibitory 
activity (Lee et al. 2000), cytotoxic effect against lymphocytic leukaemia (Duh et al. 
1992), and chemopreventive effect against colon carcinogenesis (Morioka et al. 
2004). It has been reported that coumarins (Chen et al. 1996; Ikeshiro et al. 1994, 
1993, 1992; Duh et al. 1992), chromones, polyacetylenes (Lee et al. 2000), sugar 
alcohols (Lee et al. 2004), and steroid glycosides (Shin et al. 1992) were isolated 
from the roots of P. japonicum. Phytochemical studies proved that P. japonicum 
leaves possess coumarins (Jang et al. 2008; Hisamoto et al. 2003), flavonoids, 
phenylpropanoid glycosides (Hisamoto et al. 2004), phenol derivatives, C13 
norisoprenoid glycosides, nucleosides, nucleobases, amino acids, and benzofuran 




dihydropyranocoumarins are major constituents of P. japonicum roots. 
 







































































(+)-oxypeucedanin hydrate,  
















(+)-peucedanocoumarin III,  





































































































































































































1.1.2. Angular dihydropyranocoumarins 
 
 Coumarins are divided into 4 sub-types including simple coumarins, 
furanocoumarins, pyranocoumarins, and pyrone-substituted coumarins. 
Pyranocoumarins contain a six membered ring which is connected to coumarin and 
there are two types, linear (xanthyletin type) and angular (seselin type), depending 
on the connection method. Angular-type pyranocoumarins possess khellactone 
skeleton (dihydroseselin) and the substituents are attached at the two stereocenters, 
C-3’ and C-4’. According to their relative configurations, cis-khellactones are 
generally divided into the (3’R,4’R)- and (3’S,4’S)-khellactone esters. In addition, 
enantiomers and diastereomers could occur (Sarkhail 2014). Angular 
dihydropyranocoumarins were isolated mainly from the genera Peucedanum, 
Angelica, and Seseli, which belong to the Umbelliferae family (Lee et al. 2015; Chun 
et al. 2016; Jung et al. 2012). It was reported that the khellactone esters showed anti-
inflammatory effect (Yu et al. 2012), antibacterial activity (Lu et al. 2001), tracheal 
relaxant activity (Zhao et al. 1999), monoamine oxidase inhibitory activity (Huong 
et al. 1999), antiplatelet aggregation activity (Jong et al. 1992), and anti-tumor 
activity (Duh et al. 1991). 
 
1.1.3. Inflammation and the role of nitric oxdie 
 
 Inflammation is a complex mechanism, which occurred to protect host tissue from 
injurious agents. Acute inflammation is a beneficial defense process particularly 
during infectious challenges. However, if the inflammation is persisted chronically, 
it could cause inflammatory diseases. Chronic inflammation is related to the 
infiltration of mononuclear cells, such as macrophages and lymphocytes (Kaplanski 
et al. 2003). 
 Microbial products such as lipopolysaccharide (LPS) and proinflammatory 
cytokines such as interleukins, tumor necrosis factor-α (TNF-α), and interferon-γ 
(IFN-γ) triggers the gene expression of iNOS (inducible nitric oxide synthase) in 
various inflammatory and tissue cells (Molloy et al. 1993; Korhonen et al. 2005). 




effect is aimed to protect host against invading pathogens, but it can also be harmful 
to host tissues. If NO interacts with molecular oxygen and superoxide anion, it can 
produce reactive nitrogen species. Cellular functions could be modified and it can 
play important role in inflammation (Korhonen et al. 2005). 
 
1.2. Purpose of Research 
 
The khellactone moiety was easily indicated by typical NMR patterns such as 
chemical shift and coupling constant. Based on the J value and NOESY correlation, 
the relative configuration cold be suggested. However, Mosher method or X-ray 
crystallography was required to determine the absolute configuration. Especially, in 
the case of diacyl angular dihydropyranocoumarin, pretreatment step was needed to 
produce a free 4’-OH for the Mosher method. In addition, it is difficult to make a 
fine crystal for X-ray diffraction analysis. Therefore, most of the literatures 
ambiguously reported the absolute configuration and there are few helpful references. 
In the early years, comparing the optical rotation of hydrolysate with authentic 
sample was common way to define the absolute configuration (Ikeshiro et al. 1993). 
Recently, the studies about enantioseparation and ECD measurement were reported 
(Song et al. 2012; Song et al. 2014b; Lou et al. 2004). In this study, partial hydrolysis 
prior to MTPA method, X-ray crystallography, and ECD calculation were applied to 
unambiguously determine the absolute configuration of khellactone esters.  
 Although P. japonicum roots were traditionally used as a cold medicine, there is a 
lack of research on anti-inflammatory activities at compound level. Because, a lot of 
khellactone esters were isolated in this study, the bioactivity screening of compounds 










Chapter 2. Structure Elucidation of  
Khellactone Esters 
 
2.1. Compound 1 
 
Compound 1 was obtained as colorless needles with molecular formula C23H28O7 
based on the m/z 417.1912 [M+H]+ in HRCIMS. The proton signals of an α-pyrone 
[δH 6.20 (1H, d, J = 9.5 Hz, H-3) and 7.57 (1H, d, J = 9.5 Hz, H-4)] and an ortho 
disubstituted benzene [δH 7.33 (1H, d, J = 8.6 Hz, H-5) and 6.78 (1H, d, J = 8.6 Hz, 
H-6)] revealed the presence of coumarin moiety (Figure 2). Two methines at δH 5.30 
(1H, d, J = 4.8 Hz, H-3’) and 6.53 (1H, d, J = 4.8 Hz, H-4’) and geminal dimethyls 
at δH 1.38 and 1.43 (each 3H, s, H-5’, H-6’) indicated an angular dihydropyran ring 
in this structure. The signals of an isobutyryl group were observed at δH 2.55 (1H, 
sep, J = 7.0 Hz, H-2’’), 1.18, and 1.17 (each 3H, d, J = 7.0 Hz, H-3’’, H-4’’), and that 
of 2-methylbutyryl group at δH 2.37 (1H, sxt, J = 7.0 Hz, H-2’’’), 1.71, 1.44 (each 
1H, m, H-3’’’), 0.91 (3H, t, J = 7.4 Hz, H-4’’’), and 1.19 (3H, d, J = 7.0 Hz, H-5’’’). 
The linkages between isobutyryl group (C-1’’) and H-3’ (δH 5.30), 2-methylbutyryl 
(C-1’’’) group and H-4’ (δH 6.53) were confirmed by HMBC (Figure 3). Based on 
the J value (4.8 Hz) (Macias et al. 1989; Song et al. 2012) and NOESY correlation 
between H-3’ and H-4’ (Figure 4), the relative configuration at C-3’ and C-4’ was 
identified as cis-orientation. To determine the absolute configuration, partial alkaline 
hydrolysis was performed to produce a hydroxyl group which is necessary to the 
MTPA (α-methoxy-α-trifluoromethylphenylacetyl) reaction. During alkaline 
hydrolysis, three products (1a-1c) were obtained (Scheme 6). Due to the inversion 
at 4’-position, the partial hydrolyzed product (1a) was identified as trans 
configuration based on the coupling constant between H-3’ and H-4’ (3.9 Hz). Based 
on NMR and optical rotation, the other products were assigned as (+)-trans-
khellactone (1b) and (-)-cis-khellactone (1c). The hydrolysate 1a was treated with 
the Mosher reagents to give (S)- and (R)-MTPA esters (1aa and 1ab). As a result, 




orientation (Figure 5) and that of 1 was assigned as (3’S,4’S) in consideration of the 
epimerization at the 4’ position. Furthermore, the (3’S,4’S) configuration was 
confirmed based on the crystal structure of 1, which is obtained by single-crystal X-
ray diffraction (Figure 6). The calculated ECD spectrum of 1 was in good agreement 
with the experimental ECD spectrum of 1 (Figure 7). Compound 1 was isolated for 










Figure 3. HMBC spectrum of compound 1 (400 MHz, CDCl3) 
 


















Figure 5. Δδ (δS-δR) values obtained from  






Figure 6. X-ray crystallographic structure of 1 (ORTEP drawing) 
 
 






















2.2. Compound 2 
 
Compound 2 was isolated as colorless needles. The molecular formula of 2 was 
determined to be C19H20O6 by HRESIMS. The 1H NMR spectrum of 2 was similar 
to 1, except for the 3’- and 4’-substituents. The signal of an acetyl moiety was 
observed at δH 2.07 (3H, s, H-2’’), and that of senecioyl group at δH 5.62 (1H, s, H-
2’’’), 2.21 (3H, s, H-4’’’), and 1.87 (3H, s, H-5’’’) (Figure 8). Based on HMBC 
spectrum, acetyl (C-1’’ (δC 169.9)) and senecioyl (C-1’’’ (δC 165.2)) moieties were 
connected to H-3’ (δH 5.29) and H-4’ (δH 6.56), respectively (Figure 9). The cis-
orientation at C-3’ and C-4’ was determined by J value (4.8 Hz) and NOESY 
interaction (Figure 10). Based on single-crystal X-ray diffraction analysis, the 
absolute configuration of compound 2 was identified as (3’S,4’S) (Figure 11). The 
ECD spectrum of 2 exhibited similar pattern with 1 (Figure 12). Compound 2 was 
isolated for the first time from nature and named (3’S,4’S)-3'-O-acetyl-4'-O-
senecioylkhellactone. 
 





Figure 9. HMBC spectrum of compound 2 (400 MHz, CDCl3) 
 
 






Figure 11. X-ray crystallographic structure of 2 (ORTEP drawing) 
 
 









2.3. Compound 9 
 
The molecular formula of 9 was determined as C24H28O7 by HRESIMS. The 1H 
and 13C NMR spectra of 9 indicated the presence of khellactone moiety. In the 1H 
NMR, 9 exhibited the signals of an isovaleryl moiety at δH 2.21 (1H, d, J = 7.4 Hz, 
H-2’’a), 2.20 (1H, d, J = 6.9 Hz, H-2’’b), 2.08 (1H, m, H-3’’), 0.94 (3H, d, J = 6.6 
Hz, H-4’’), and 0.93 (3H, d, J = 6.6 Hz, H-5’’), and that of angeloyl group at δH 6.01 
(1H, q, J = 7.3 Hz, H-3’’’), 1.98 (3H, d, J = 7.3 Hz, H-4’’’), and 1.84 (3H, s, H-5’’’) 
(Figure 13). The connection between isovaleryl (C-1’’) group and H-3’, and 
angeloyl (C-1’’’) group and H-4’ was confirmed by HMBC correlations (Figure 14). 
The configuration between 3’ and 4’ position was assigned as cis based on the J 
value (4.9 Hz) and the presence of NOESY correlation (Figure 15). The ECD 
spectrum of 9 was in good agreement with the ECD spectra of 1 and 2 (Figure 12). 
Therefore, the absolute configuration of 9 could be determined as 3’S and 4’S. 
Compound 9 was newly isolated from nature and named (3’S,4’S)-4'-O-angeloyl-3'-
O-isovalerylkhellactone. 
 





Figure 14. HMBC spectrum of compound 9 (800 MHz, CDCl3) 
 
 









2.4. Compounds 8, 10, 11, and 15 
 
The molecular formula of 8 was determined to be C23H28O7 using HRESIMS. 
Similar to 1, compound 8 was inferred to have khellactone and 2-methylbutyryl 
moieties from 1H NMR spectrum. Compound 8 possessed n-butyryl group, whose 
1H signals were observed at δH 2.30 (2H, dt, J = 7.4, 1.7 Hz, H-2’’), 1.66 (2H, sxt, J 
= 7.4 Hz, H-3’’), and 0.95 (3H, t, J = 7.4 Hz, H-4’’), instead of isobutyryl group 
(Figure 16). The connectivity between khellactone, butyryl, and 2-methylbutyryl 
moieties were deduced by HMBC correlations. The configurations of (3’S,4’S) were 
identified by J value (4.9 Hz), NOESY correlation, and similar ECD pattern with 1 
(Figure 12). Compound 8 was firstly isolated from nature and named (3’S,4’S)-3'-O-
butyryl-4'-O-(2-methylbutyryl)khellactone. 
Compound 10 had the molecular formula C21H24O8, suggested by HRCIMS. 
Different to compound 2, 10 showed 3-hydroxyisovaleryl signals at δH 2.59 (1H, d, 
J = 15.4 Hz, H-2’’’a), 2.50 (1H, d, J = 15.4 Hz, H-2’’’b), 1.34 (3H, s, H-4’’’), and 
1.33 (3H, s, H-5’’’), instead of senecioyl moiety (Figure 17). Based on HMBC 
spectrum, it was determined that acetyl and 3-hydroxyisovaleryl moieties were 
located at 3’ and 4’, respectively. The 3’S,4’S configurations were established by 
coupling constant (4.8 Hz), NOESY interaction, and similar ECD spectrum with 2 
(Figure 12). Compound 10 was named (3’S,4’S)-3'-O-acetyl-4'-O-(3-
hydroxyisovaleryl)khellactone and it was firstly isolated from nature. 
Compound 11 possessed the molecular formula C21H24O8, indicated by HRESIMS. 
The 1H NMR spectrum suggested that 11 was similar to 2 except for the 3-hydroxy-
2-methylbutyryl signals at δH 2.49 (1H, qui, J = 7.2 Hz, H-2’’’), 3.92 (1H, m, H-3’’’), 
1.22 (3H, d, J = 6.3 Hz, H-4’’’), 1.16 (3H, d, J = 7.2 Hz, H-5’’’), and 3.52 (1H, d, J 
= 5.4 Hz, 3’’’-OH) (Figure 18). In the HMBC spectrum, the interaction between H-
4’ and the carbonyl carbon (C-1’’’) of 3-hydroxy-2-methylbutyryl moiety was 
confirmed. The absolute configuration was identified as (3’S,4’S) based on the 
coupling constant (4.9 Hz), a NOESY correlation, and similar ECD pattern with 2 
(Figure 12). Compound 11 was named (3’S,4’S)-3'-O-acetyl-4'-O-(3-hydroxy-2-
methylbutyryl)khellactone and it was newly isolated from nature. 




by HRESIMS. The 1H NMR spectrum indicated that 15 had differnce with 1 at the 
3’- and 4’- stubstituents (Figure 19). Especially, the upshifted signal at δH 4.83 (1H, 
d, J = 4.6 Hz, H-4’) and methoxy signal at δH 3.70 (3H, s, 4’-OMe) were observed. 
From the HMBC spectrum, the location of 2-methylbutyryl and methoxy groups was 
established. The (3’S,4’S) configuration was suggested by the J value (4.9 Hz), a 
NOESY correlation, and similar ECD pattern with 1 (Figure 12). Compound 15 was 

















































2.5. Compounds 6 
 
The molecular formula of 6, C23H28O7, was indicated by HRCIMS. Different to 1, 
compound 6 possessed isovaleryl moiety, whose 1H signals were obatained at δH 
2.28 (1H, dd, J = 14.4, 6.7 Hz, H-2’’’a), 2.17 (1H, m, H-2’’’b), 2.13 (1H, m, H-3’’’), 
0.97 (3H, d, J = 6.3 Hz, H-4’’’), and 0.95 (3H, d, J = 6.3 Hz, H-5’’’) (Figure 20). 
HMBC correlations between H-3’/C-1’’ and H-4’/C-1’’’ determined the connectivity 
of khellactone, isobutyryl, and isovaleryl moieties. The (3’S,4’S) configurations 
were established by J value (4.9 Hz) and NOESY correlation between H-3’ and H-
4’, and similar ECD pattern with 1 (Figure 12). Compound 6 was named (3’S,4’S)-















2.6. Compounds 3, 4, 7, and 13 
Compound 3 was obtained as colorless needles. It has the molecular formula 
C23H28O7, suggested by HRCIMS. In the 1H and 13C NMR spectra, the signals of 
compound 3 was similar to compound 1 (Figure 21). Based on HMBC spectrum, 
the attachment of 2-methylbutyryl at C-3’ and isobutyryl at C-4’ was confirmed. As 
a result, compound 3 was positional isomer of compound 1. The J value (4.9 Hz) and 
NOESY interaction between H-3’ and H-4’, and similar ECD pattern with 1 revealed 
the 3’S,4’S configurations (Figure 12). Compound 3 was determined as (3’S,4’S)-4'-
O-isobutyryl-3'-O-(2-methylbutyryl)khellactone and it was firstly isolated from 
nature. 
Compound 4 possessed the molecular formula C24H28O7, which was established 
by HRCIMS. The 1H NMR spectrum of 4 suggested that it was similar to 3 except 
for the senecioyl signals (Figure 22). Based on HMBC correlation and MS 
fragmentation (base peak, M+ - OSen), the connection of senecioyl group to 4’-
position of khellactone was confirmed. Based on the coupling constant (4.9 Hz), a 
NOESY correlation, and similar ECD pattern with 3, the absolute configuration was 
assigned as (3’S,4’S) (Figure 12). Compound 4 was determined as (3’S,4’S)-3'-O-(2-
methylbutyryl)-4'-O-senecioylkhellactone, which was newly isolated from nature. 
The molecular formula of compound 7, C24H28O7, was suggested by HRESIMS. 
The 1H NMR spectrum of 7 resembled that of 3 except for angeloyl group signals 
(Figure 23). The HMBC correlation revealed the connectivities between 2-
methylbutyryl group (C-1’’) and H-3’, and angeloyl group (C-1’’’) and H-4’. The 
configuration was established as (3’S,4’S) based on the J value (4.9 Hz), a NOESY 
correlation, and similar negative and positive Cotton effects with 1 (Figure 12). 
Compound 7 was acquired for the first time from nature and named (3’S,4’S)-4'-O-
angeloyl-3'-O-(2-methylbutyryl)khellactone. 
Compound 13 had the molecular formula C19H22O6, was determined by HRESIMS. 
Different to 3, the upshifted signal at δH 5.40 (1H, d, J = 4.9 Hz, H-4’) and hydroxy 
signal at δH 3.12 (1H, br s, 4’-OH) were observed, which means that compound 13 
was monoacylkhellactone (Figure 24). HMBC correlations between H-3’ and C-1’’ 




and NOESY interaction between H-3’ and H-4’, and similar ECD pattern with 3, the 
(3’S,4’S) configurations were assigned (Figure 12). Compound 13 was newly 
isolated from nature and named (3’S,4’S)-3'-O-(2-methylbutyryl)khellactone. 
 
 
Figure 21. 1H and 13C NMR spectra of compound 3 (400/100 MHz, CDCl3) 
 






Figure 23. 1H and 13C NMR spectra of compound 7 (500/125 MHz, CDCl3) 
 
 









2.7. Compounds 5 and 21, 22, and 23 
 
Compound 5 was isolated as white amorphous powder and its molecular formula 
C23H28O7 was suggested by HRCIMS. In the 1H and 13C NMR spectra, the signals of 
compound 5 resembled that of compound 4 (Figure 25). From the HMBC 
correlations, senecioyl and 2-methylbutyryl moieties were positioned to C-3’ and C-
4’, respectively. Based on above finding, compound 5 was positional isomer of 
compound 4. The J value (5.0 Hz) and NOESY correlation of H-3’ and H-4’, and 
similar ECD pattern with 4 suggested the 3’S,4’S configurations (Figure 12). 
Compound 5 was assigned as (3’S,4’S)-4'-O-(2-methylbutyryl)-3'-O-senecioyl 
khellactone and it was firstly isolated from nature. 
The molecular formulas of compounds 21-23 were indicated by ESIMS. The 1H 
NMR spectra of 21-23 were similar to 5, except for the 4’-substituent. (Figures 26-
28). The 3’-senecioyl khellactone moiety was confirmed by HMBC correlation 
between carbonyl carbon (C-1’’) of senecioyl group and H-3’ or MS fragmentation 
(m/z 327, M+ - OR2, R2 = 4’-substituent). The J value (4.8-5.0 Hz) between H-3’ and 
H-4’ and similar ECD pattern with 5 established the 3’S,4’S configurations (Figure 
12). Compounds 21-23 were identified as (3’S,4’S)- 4'-O-angeloyl-3'-O-
senecioylkhellactone (Wang et al. 2015), (3’S,4’S)- 3',4'-di-O-senecioylkhellactone 
(Lee et al. 2014), and (3’S,4’S)-4'-O-isovaleryl-3'-O-senecioylkhellactone 






Figure 25. 1H and 13C NMR spectra of compound 5 (600/150 MHz, CDCl3) 
 
 






Figure 27. 1H and 13C NMR spectra of compound 22 (500/125 MHz, CDCl3) 
 
 















2.8. Compounds 12, 24, 25, 26, 27, and 40 
 
Compound 12 possessed the molecular formula C21H24O7, determined by 
HRESIMS. In the 1H NMR spectrum, 12 displayed 2-methylbutyryl signals at δH 
2.35 (1H, sxt, J = 7.0 Hz, H-2’’’), 1.66 (1H, m, H-3’’’a), 1.41 (1H, m, H-3’’’b), 0.88 
(3H, t, J = 7.4 Hz, H-4’’’), and 1.15 (3H, d, J = 7.0 Hz, H-5’’’), dinstinct from 
compound 2 (Figure 29). By the HMBC experiment, it was suggested that acetyl 
and 2-methylbutyryl groups were positioned at 3’ and 4’, respectively. The 3’S,4’S 
configurations were confirmed by coupling constant (4.9 Hz), NOESY correlation, 
and similar ECD pattern with 2 (Figure 12). Compound 12 was isolated for the first 
time from nature and named (3’S,4’S)-3'-O-acetyl-4'-O-(2-methylbutyryl) 
khellactone. 
The molecular formulas of compounds 24-27, and 40 were determined using 
ESIMS. Similar to 12, the signals of khellactone and 3’-substituent were detected in 
the 1H NMR spectra of 24-27, and 40 (Figures 30-34). In the case of 24, it was 
indicated as monoacylkhellactone based on the upshifted signals at δH 5.40 (1H, d, J 
= 5.0 Hz, H-4’). The HMBC correlation between acetyl group (C-1’’) and H-3’ 
revealed the presence of 3’-acetylkhellactone ester moieties of 25-27, and 40. The 
relative configuration was established as cis-orientation based on the coupling 
constant (4.8-5.0 Hz) between H-3’ and H-4’. In comparison with the ECD spectrum 
of 12, the absolute configurations of 24-27 and 40 were determined as 3’S,4’S and 
3’R,4’R, respectively (Figures 12 and 35). The structures of 24-27, and 40 were 
assigned to be (3’S,4’S)-3'-O-acetylkhellactone (qianhucoumarin B) (Kong et al. 
1996; Kong et al. 1993), (3’S,4’S)- 3’-O-acetyl-4’-O-angeloylkhellactone (pteryxin) 
(Song et al. 2014), (3’S,4’S)-3'-O-acetyl-4'-O-isobutyrylkhellactone (hyuganin D) 
(Wang et al. 2015), (3’S,4’S)-3'-O-acetyl-3'-O-isovalerylkhellactone (suksdorfin, 
corymbocoumarin) (Tosun et al. 2005), and (3’R,4’R)-3’,4’-di-O-acetylkhellactone 







Figure 29. 1H and 13C NMR spectra of compound 12 (400/100 MHz, CDCl3) 
 
 






Figure 31. 1H and 13C NMR spectra of compound 25 (400/100 MHz, CDCl3) 
 
 






Figure 33. 1H and 13C NMR spectra of compound 27 (600/150 MHz, CDCl3) 
 
 







































2.9. Compounds 14 and 28, 29, and 30 
 
Compound 14 was isolated as white amorphous powder and its molecular formula 
C19H22O6 was determined by HRESIMS. The 1H NMR spectrum of 14 was similar 
to 13 except for the upshifted signal at δH 4.01 (1H, d, J = 4.7 Hz, H-3’), downshifted 
signal at δH 6.36 (1H, d, J = 4.7 Hz, H-4’), and hydroxy signal at δH 2.96 (1H, br s, 
3’-OH) (Figure 36). In the HMBC spectrum, H-3’ displayed correlations with 
carbonyl carbon (C-1’’) of 2-methylbutyryl group. The 3’S,4’S configuration was 
assigned by the coupling constant (4.7 Hz), NOESY correlation, and a Cotton effect 
at 318 nm (Figure 12). Compound 14 was newly isolated from nature and named 
(3’S,4’S)-4'-O-(2-methylbutyryl)khellactone. 
Using ESIMS, the molecular formulas of compounds 28-30 were indicated. The 
1H NMR spectra of 28-30 resembled that of 14, whose signals revealed the presence 
of khellactone and 4’-substituent except for 28 (Figures 37-39). The J value (4.6-4.7 
Hz) between H-3’ and H-4’ and a Cotton effect at 326-328 nm in the ECD spectra 
suggested the absolute configurations of 28-30 as 3’S,4’S (Figure 12).  Compounds 
28-30 were assigned as (-)-cis-khellactone (Wang et al. 2015), (3’S,4’S)-4'-O-
acetylkhellactone (qianhucoumarin C) (Kong et al. 1993), and (3’S,4’S)-3’-hydroxy-
4’-O-angeloyloxy-3’,4’-dihydroseselin (Tosun et al. 2005). 
 






Figure 37. 1H and 13C NMR spectra of compound 28 (400/100 MHz, CD3OD) 
 
 




































2.10. Compounds 31, 32, 33, and 34 
 
Based on ESIMS, the molecular formulas of compounds 31-34 were established. 
Similar to 1, the 1H NMR spectra of 31-34 revealed the presence of khellactone and 
angeloyl group, instead of isobutyryl group at 3’-position (Figures 40-43). The 
presence of 3’-angeloylkhellactone moieties of 31 and 33-34 was confirmed by 
HMBC interactions. The J value (4.8-4.9 Hz) and NOESY interaction between H-3’ 
and H-4’ and a negative Cotton effect at 324-328 nm suggested the 3’S,4’S 
configurations of 31-34 (Figures 12). Therefore, the structures of compounds 31-34 
were assigned to be (3’S,4’S)-3'-O-angeloyl-4'-O-(2-methylbutyryl)khellactone 
(praeruptorin F) (Lv et al. 2013), (3’S,4’S)-3',4'-di-O-angeloylkhellactone (anomalin, 
praeruptorin B) (Song et al. 2012), (3’S,4’S)-3’-O-angeloyloxy-4’-hydroxy-3’,4’-
dihydroseselin (Tosun et al. 2005), and (3’S,4’S)-3’-O-angeloyl-4’-O-
senecioylkhellactone (calipteryxin) (Song et al. 2012). 
 
 






Figure 41. 1H and 13C NMR spectra of compound 32 (400/75 MHz, CDCl3) 
 
 




































2.11. Compounds 35, 36, and 37 
 
Compounds 35-37 were obtained as white amorphous powders, whose molecular 
formulas were indicated based on ESIMS. The 1H NMR spectra of 35-37 displayed 
the signals of khellactone and isovaleryl moiety, which resembles that of 9 (Figures 
44-46). The HMBC interaction or MS fragmentation (m/z 329, M+ - OR2, R2 = 4’-
substituent) revealed that 35-37 are possessing 3’-isovalerylkhellactone moiety. The 
coupling constant (4.6-5.1 Hz) between H-3’ and H-4’ and a negative Cotton effect 
at 323-326 nm indicated that the configurations of 31-34 were 3’S,4’S (Figure 12). 
Compounds 35-37 were assigned as (3’S,4’S)-3'-O-isovaleryl-4'-O-
senecioylkhellactone (Lee et al. 2014), (3’S,4’S)-3',4'-di-O-isovalerylkhellactone 
(Song et al. 2012), and (3’S,4’S)-3'-O-isovaleryl-4'-O-(2-methylbutyryl) khellactone 
(praeruptorin H) (Lv et al. 2013). 
 
 






Figure 45. 1H and 13C NMR spectra of compound 36 (300/75 MHz, CDCl3) 
 
 







2.12. Compounds 38 and 39 
 
Compounds 38-39 were isolated as white amorphous powder, whose molecular 
formulas C19H20O5 and C19H22O5 were suggested by ESIMS. The proton signals of 
methine and methylene in pyran were observed [38: δH 5.13 (1H, t, J = 4.9 Hz, H-
3’), 3.18 (1H, dd, J = 18.0, 4.9 Hz, H-4’a), and 2.98 (1H, dd, J = 18.0, 4.9 Hz, H-
4’b); 39: δH 5.12 (1H, t, J = 5.2 Hz, H-3’), 3.18 (1H, dd, J = 17.8, 5.2 Hz, H-4’a), 
and 2.94 (1H, dd, J = 17.8, 5.2 Hz, H-4’b)], which indicated the presence of angular 
3’-acyloxypyranocoumarin moiety (Figures 47-48). The ECD spectra of 38-39 
showed similar pattern with that of 40, so the inferred absolute configurations of 38-
39 were 3’S (Figure 35). In comparison with the optical rotation and spectral data in 
the literature, compounds 38-39 were determined as (3’R)-O-senecioyllomatin and 




























2.13. Compounds 16, 17, 18, 19, and 20 
 
Compound 16, E1 (enantiomeric mixture of 17 and 18), and E2 (enantiomeric 
mixture of 19 and 20) were isolated from same fraction, H39. Compound 16 
possessed the molecular composition C19H20O6, indicated by HRCIMS (m/z 
345.1335 [M+H]+). In the 1H and 13C NMR spectra, 16 showed resemblance with its 
diastereomer 17, except for the proton and carbon signals at δH 6.08 (1H, d, J = 3.4 
Hz, H-4’), δC 67.8 (C-4’), whereas that of 17 was displayed at δH 6.43 (1H, d, J = 4.8 
Hz, H-4’), δC 63.0 (C-4’) (Figure 49). Because of the coupling constant (3.4 Hz) and 
the absence of a NOESY interaction, the relative configuration at the 3’ and 4’-
positions was suggested as trans. The absolute configuration of 16 at 3’-position was 
established as S based on the Mosher method (Figure 50). Due to the trans 
orientation between the 3’ and 4’ positions, the configuration at the 4’ position was 
assigned as R. The experimental ECD spectrum of 16 was in good agreement with 
the calculated ECD spectrum of that (Figure 51). Based on the above findings, 
Compound 16 was determined to be (3’S,4’R)-4'-O-senecioylkhellactone and it was 
isolated for the first time from nature.  
To determine the absolute configuration, E1 (enantiomeric mixture of compounds 
17 and 18) was derivatized by the Mosher reagents. After MTPA reaction of E1, the 
(S)-MTPA esters 17a and 18a, and (R)-MTPA esters 17b and 18b were isolated by 
HPLC. The absolute configurations of 17 and 18 were suggested as 3’S,4’S and 
3’R,4’R based on the Mosher method (Figure 52). 
Based on the 1H and 13C NMR spectra, it was revealed that compounds 19 and 20 
were positional isomer of compounds 17 and 18 (Figures 54-57). In the same manner 
with 17 and 18, the configurations of 19 and 20 were determined as 3’S,4’S and 
3’R,4’R (Figure 53). 
After discovering enantiomeric mixtures (E1 and E2), enantioseparation was 
carried out on a chiral-selective column. From E1 and E2, compounds 17 and 18, 
and 19 and 20 were isolated, respectively. Based on the opposite optical rotations, 
mirror symmetric ECD patterns, and similar NMR spectra, the structures of the 
enantiomers were confirmed. In addition, the calculated ECD spectra of 17-20 




spectra of them (Figures 58-61). Because of similar ratios of the MTPA reaction 
products and enantioseparation products, RP-HPLC analysis of MTPA esters could 
be an alternative way to confirm the enantiomer existence. Taken together, the 
structure of compounds 17-20 were assigned to be (3’S,4’S)-4'-O-
senecioylkhellactone, (3’R,4’R)-4'-O-senecioyl khellactone, (3’S,4’S)-3'-O-
senecioylkhellactone, and (3’R,4’R)-3'-O-senecioyl khellactone (Ikeshiro et al. 1993; 
M. Swager and H. Cardellina Ii 1985; Gonzalez et al. 1979). 
 
 




















































18b R=(R)-MTPA ester  



























20b R=(R)-MTPA ester  



















Figure 54. 1H and 13C NMR spectra of compound 17 (600/150 MHz, CDCl3) 
 
 






Figure 56. 1H and 13C NMR spectra of compound 19 (600/150 MHz, CDCl3) 
 
 









Figure 58. Experimental ECD spectra of 16-18 
 
 










































Figure 60. Experimental ECD spectra of 19-20 
 















































Chapter 3. Structure Elucidation of  
Angular Furanocoumarins 
 
3.1. Compounds 41-43 
 
In HRCIMS, molecular ion peak of 41 was observed at m/z 361.1284 [M+H]+ and 
its molecular composition was established as C19H20O7. In comparison with the 1H 
and 13C NMR spectra of pyranocoumarin 17, the signals at δH 6.74 (1H, s, H-3’) and 
4.20 (1H, br s, 2’-OH), and δC 112.8 (C-2’) exhibited significant differences, which 
revealed the presence of angular monohydro-monohydroxy-furanocoumarin 
skeleton (Figure 62). The attachment of isopropyl group, angular furan, coumarin, 
and senecioyl group was confirmed by HMBC correlations of H-5' and H-6’ with C-
2’ and C-4’, and of 2'-OH with C-2’, C-3’, and C-4’, and of H-3' with C-2’, C-4’, C-
7, C-8, C-9, and C-1’’ (Figures 63-64). Due to the intramolecular seven-membered 
ring hydrogen bonding between 2’-OH and 1’’-carbonyl group, the proton signal of 
2’-OH was displayed at δH 4.20 (br s), which indicated trans-orientation at 2’ and 3’-
positions. The experimental ECD spectrum of 41 showed the similar pattern with the 
calculated ECD spectrum of 2’R,3’R isomer (Figure 65). Therefore, the structure of 
41 was determined as (2’R,3’R)-2’-hydroxy-3’-O-senecioylvaginol and it was 
isolated first time from nature. 
In the same manner, angular monohydro-monohydroxy-furanocoumarin moiety of 
42 and 43 was suggested based on 1D and 2D NMR spectra (Figures 66 and 68). The 
trans configuration at 2’ and 3’-position was confirmed by intramolecular hydrogen 
bonding between 2’-OH and carbonyl oxygen at C-1’’. Comparing the calculated 
ECD spectra of 42-43 to the experimental ECD spectra, the absolute configuration 
was indicated as 2’R,3’R (Figures 67 and 69). Compounds 42 and 43 were assinged 
to be (2’R,3’R)-2’-hydroxy-3’-O-(2-methylbutyryl)vaginol and (2’R,3’R)-2’-
















Figure 64. HMBC spectrum of compound 41 (500 MHz, CDCl3) 
 






Figure 66. 1H and 13C NMR spectra of compound 42 (400/100 MHz, CDCl3) 
 






Figure 68. 1H and 13C NMR spectra of compound 43 (500/125 MHz, CDCl3) 
 






3.2. Compound 48 
 
Compound 48 was acquired as white amorphous powder and its molecular 
composition C19H20O6 was indicated by ESIMS. Different to 41, the 1H and 13C NMR 
spectra of 48 revealed the presence of angular dihydrofuran moiety, whose signals 
were observed at δH 6.98 (1H, d, J = 6.6 Hz, H-3’) and 6.98 (1H, d, J = 6.6 Hz, H-
2’), and δC 94.4 (C-2’) (Figure 70). The relative configuration at 2’ and 3’-position 
was defined as cis based on the J value (6.6 Hz). Therefore, the structure of 48 was 
identified as 3’-O-senecioylvaginidiol (Mohammadi et al. 2010). 
 







Chapter 4. Structure Elucidation of  
Other Compounds 
 
4.1. Compound 44 
 
Compound 44 was obtained as white amorphous powder. Its molecular composition 
C14H14O4 was determined by ESIMS. In the 1H NMR spectrum of 44, the presence 
of linear-type dihydrofuranocoumarin moiety was revealed based on the signals of 
two singlet methines at δH 7.39 (1H, s, H-5) and 6.71 (1H, s, H-8) and the signals of 
isopentyl moiety at δH 4.74 (1H, dd, J = 9.0, 8.4 Hz, H-2’), 3.24 (2H, m, H-3’), 1.28 
(3H, s, H-5’), and 1.22 (3H, s, H-6’) (Figure 71). In comparison with the optical 
rotation in the literature, compound 44 was defined as (+)-marmesin (nodakenetin) 
(Znati et al. 2014; Jiang et al. 2011). 
 







4.2. Compounds 45-47 
 
The molecular composition of compound 45 was established as C18H20O7 based on 
ESIMS. The proton signals of two doublet methines at δH 7.83 (1H, d, J = 2.3 Hz, 
H-2’), 7.23 (1H, d, J = 2.3 Hz, H-3’) revealed the furanocoumarin moiety in this 
structure (Figure 72). In the proton NMR, the signals of 5-OMe and isopentyl group 
at C-8 were also observed. The 5-OMe was located at C-5 based on the NOESY 
correlation of 5-OMe with H-3’ and H-4. The structure of 45 was identified as 9-(2-
hydroxy-3-methoxy-3-methylbutoxy)bergapten (Bergendorff et al. 1997). 
The molecular formulas of compounds 46 and 47 were determined by ESIMS. 
Based on the proton signals of two methines [46: δH 7.57 (1H, d, J = 2.4 Hz, H-2’), 
6.93 (1H, dd, J = 2.4, 0.9 Hz, H-3’); 47: δH 7.58 (1H, d, J = 2.4 Hz, H-2’), 6.98 (1H, 
dd, J = 2.4, 0.8 Hz, H-3’)], furanocoumarin moieties were suggested (Figures 73 and 
74). The structure of linear-type furanocoumarin without substituent at C-8 position 
was confirmed by the carbon signals at [46: δC 94.2 (C-8); 47: δC 94.5 (C-8)]. The 
substituents at C-8 were indicated by 1H and 13C NMR spectra. Therefore, the 
structures of 46 and 47 were assigned as isoimperatorin and 5-(2-hydroxy-3-
methoxy-3-methylbutoxy) psoralen (Bergendorff et al. 1997). 
 





Figure 73. 1H and 13C NMR spectra of compound 46 (300/75 MHz, CDCl3) 
 





4.3. Compound 49 
 
The molecular formula of compound 49, C19H20O5, was established by ESIMS. The 
presence of linear-type pyranocoumarin moiety was indicated based on the proton 
signals of two singlet methines at δH 7.12 (1H, s, H-5) and 6.77 (1H, s, H-8) and 
isopentyl moiety at δH 5.06 (1H, t, J = 4.8 Hz, H-3’), 3.17 (1H, dd, J = 17.0, 4.8 Hz, 
H-4’a), 2.84 (1H, dd, J = 17.0, 4.8 Hz, H-4’b), 1.36 (3H, s, H-5’), and 1.34 (3H, s, 
H-6’) (Figure 75). The signals of senecioyl moieties were also observed in 1H NMR 
δH at 5.64 (1H, br s, H-2’’), 2.12 (3H, br s, H-4’’), and 1.85 (3H, br s, H-5’’). In 
comparison with the optical rotation in the literature, the structure of 49 was 
identified as (S)-(+)-decursin (Lee et al. 2010; Kim et al. 2016). 
 
 










4.4. Compounds 50-51 
 
The molecular formula of compound 50 was determined to be C14H14O4 by ESIMS. 
In the 1H NMR spectrum, 7,8-disubstituted coumarin moiety was established, whose 
signals were observed at δH 7.81 (1H, d, J = 9.4 Hz, H-4), 7.29 (1H, d, J = 8.5 Hz, 
H-5), 6.80 (1H, d, J = 8.5 Hz, H-6), 6.16 (1H, d, J = 9.4 Hz, H-3) (Figure 76). In 
addition, the isopentyl group was indicated based on the signals at δH 5.53 (1H, t, J 
= 7.3 Hz, H-2’), 3.89 (2H, s, H-4’), 3.56 (2H, d, J = 7.3 Hz, H-1’), and 1.87 (3H, s, 
H-5’). Therefore, the structure of 50 was determined as isoarnottinin (Elgamal et al. 
1993). 
Compound 51 was isolated as white amorphous powder and its molecular formula 
C9H6O3 was established by ESIMS. Based on the 1H NMR, 7-hydroxycoumarin 
moiety was confirmed [δH 9.74 (1H, s, 7-OH), 7.84 (1H, d, J = 9.4 Hz, H-4), 7.44 
(1H, d, J = 8.5 Hz, H-5), 6.78 (1H, dd, J = 8.5, 2.2 Hz, H-6), 6.70 (1H, d, J = 2.2 Hz, 
H-8), 6.17 (1H, d, J = 9.4 Hz, H-3)] (Figure 77). The structure of 51 was identified 
as umbelliferone (Li et al. 2014). 
 































4.5. Compounds 52-55 
 
The molecular composition of compound 52, C11H10O4 was established by ESIMS. 
The 6,7-dimethoxycoumarin moiety was indicated based on the proton signals at δH 
7.86 (1H, d, J = 9.4 Hz, H-4), 7.12 (1H, s, H-5), 6.96 (1H, s, H-8), 6.24 (1H, d, J = 
9.4 Hz, H-3), 3.90 (3H, s, 7-OMe), 3.86 (3H, s, 6-OMe) (Figure 78). The structure 
of 52 was determined to be scoparone (Vila-Nova et al. 2013). 
Based on ESIMS, the molecular formulas of compounds 53-55 were indicated. The 
presence of 6,7-disubstituted coumarin moiety was suggested based on the proton 
signals of two singlet methines (H-5 and H-8) (Figures 79-81). The signals of 
isopentyl groups were observed in 1H NMR [53: δH 4.76 (1H, br s, H-4’a), 4.72 (1H, 
br s, H-4’b), 4.27 (1H, dd, J = 7.9, 5.7 Hz, H-2’), 2.93 (1H, dd, J = 13.6, 5.7 Hz, H-
1’a), 2.74 (1H, dd, J = 13.6, 7.9 Hz, H-1’b), and 1.77 (3H, s, H-5’); 54: δH 6.29 (1H, 
dd, J = 12.7, 0.6 Hz, H-1’), 5.81 (1H, d, J = 12.7 Hz, H-2’), and 1.26 (6H, s, H-4’, 
H-5’); 55: δH 5.21 (1H, t, J = 7.4 Hz, H-2’), 3.23 (2H, d, J = 7.4 Hz, H-1’), 1.70 (3H, 
s, H-4’), and 1.64 (3H, s, H-5’)]. In addition, 7-OMe groups were also confirmed by 
1H NMR spectra. Therefore, the structures of 53-55 were assigned as tamarin 
(isosuberenol) (Gonzalez et al. 1977), (Z)-suberenol (Juichi et al. 1988), and 





Figure 78. 1H and 13C NMR spectra of compound 52 (600/150 MHz, CD3OD) 
 






Figure 80. 1H and 13C NMR spectra of compound 54 (400/100 MHz, CD3OD) 
 




4.6. Compounds 56-58 
 
Compound 56 possessed the molecular formula C14H16O5, which was indicated by 
ESIMS. The presence of 6,7-disubstituted coumarin moiety was established based 
on the proton signals of two singlet methines at δH 7.38 (1H, s, H-5) and 6.71 (1H, s, 
H-8) and the signals of isopentyl moiety were also observed at δH 3.60 (1H, d, J = 
10.4 Hz, H-2’), 3.07 (1H, d, J = 14.0 Hz, H-1’a), and 2.53 (1H, dd, J = 14.0, 10.4 
Hz, H-1’b), 1.24 (6H, s, H-4’, H-5’) (Figure 82). The structure of 56 was identified 
as peucedanol (Ikeshiro et al. 1994). 
The molecular compositions of 57 and 58 were suggested by ESIMS. The 1H NMR 
spectra of 57 and 58 were similar to that of 56, except for the signals of glucosyl and 
apiosyl moieties of 57 and 58 (Figures 83-84) The anomeric proton signals of 
glucosyl and apiosyl groups were observed [57: δH 4.96 (1H, d, J = 7.2 Hz, H-1’’); 
58: 4.97 (1H, d, J = 2.6 Hz, H-1’’’), 4.90 (1H, d, J = 7.3 Hz, H-1’’)]. The 
connectivities between sugar moiety and coumarin were confirmed by the HMBC 
correlations [57: H-1’’/C-7; 58: H-1’’’/C-6’’ and H-1’’/C-7]. Therefore, the structures 
of 57-58 were determined as peucedanol 7-O-β-D-glucopyranoside and 
peujaponiside (Ikeshiro et al. 1994). 
 





Figure 83. 1H and 13C NMR spectra of compound 57 (400/100 MHz, CD3OD) 
 




4.7. Compound 59 
 
Based on ESIMS, the molecular composition of compound 59 was established as 
C11H10O4. In the proton NMR spectrum, the presence of chromone moiety was 
revealed, whose signals were observed as two doublet methines with meta-coupling 
[δH 6.34 (1H, d, J = 2.2 Hz, H-8) and 6.32 (1H, d, J = 2.2 Hz, H-6)], one singlet 
methine [δH 6.01 (1H, s, H-3)], and one singlet methyl [δH 2.33 (3H, s, 2-Me)] 
(Figure 85). In comparison with the literature, the structure of 59 was defined as 
eugenin (Shul'ts et al. 2012). 
 











4.8. Compounds 60-61 
 
Compound 60 had the molecular formula C18H18O6, which was determined by 
ESIMS. The proton NMR spectrum of 60 revealed the presence of partial structures, 
whose signals were observed as 1,2,4-trisubstituted benzene [δH 7.09 (1H, d, J = 1.6 
Hz, H-2), 7.00 (1H, dd, J = 8.5, 1.6 Hz, H-6), and 6.79 (1H, d, J = 8.5, H-5)], para-
disubstituted benzene [δH 7.24 (2H, d, J = 8.5 Hz, H-2’, H-6’) and 6.79 (2H, d, J = 
8.5, H-3’, H-5’)], double bond with trans-orientation [δH 7.59 (1H, d, J = 15.9 Hz, 
H-7) and 6.33 (1H, d, J = 15.9 Hz, H-8)], and –CH(OH)CH2O- subunit [δH 4.87 (1H, 
m, H-7’), 4.23 (2H, m, H-8’)] (Figure 86). The connectivities of partial structures 
were confirmed by the HMBC interactions between H-7 and C-1, 2, 6, 8, and 9 and 
H-8’ and C-1’, 7’, and 9. Therefore, the structure of 60 was elucidated as 6,β-
dihydroxyphenethyl trans-ferulate (decursidate) (Yakabe et al. 2012). 
The molecular formula of compound 61, C18H18O5, was indicated by ESIMS. 
Different to 60, the proton NMR spectrum of 61 showed the signals of cis-oriented 
olefinic group at δH 6.86 (1H, d, J = 12.8 Hz, H-7) and 5.78 (1H, d, J = 12.8 Hz, H-
8) and –OCH2-CH2- subunit at δH 4.29 (2H, t, J = 7.1 Hz, H-8’) and 2.86 (2H, t, J = 
7.1 Hz, H-7’), instead of trans-oriented double bond and –CH(OH)CH2O- subunit 
(Figure 87). The HMBC correlations from H-7 to C-2, 6, and 9 and from H-8’ to C-
1’, 7’, and 9 suggested the connections of partial structures. Taken together, the 







Figure 86. 1H and 13C NMR spectra of compound 60 (500/125 MHz, CD3OD) 
 




4.9. Compound 62 
 
Compound 62 had molecular formula, C20H22O6, which was established by ESIMS 
(m/z 381 [M+Na]+). In the 1H and 13C NMR, only 10 proton and 10 carbon signals 
were detected. In consideration of the lack of the number of protons and carbons, 
perfectly symmetric structure could be inferred. In 1H NMR spectrum, the partial 
structures signals were observed, which were suggested as 1,2,4-trisubstituted 
aromatic rings [δH 6.92 (2H, d, J = 1.8 Hz, H-2, H-2’), 6.79 (2H, dd, J = 8.1, 1.8 Hz, 
H-6, H-6’), 6.74 (2H, d, J = 8.1 Hz, H-5, H-5’)] and –OCH-CH-CH2O- bridges [δH 
4.68 (2H, d, J = 4.4 Hz, H-7, H-7’), 4.21 (2H, dd, J = 9.2, 7.0 Hz, H-9a, H-9’a), 3.82 
(2H, dd, J = 9.2, 3.7 Hz, H-9b, H-9’b), 3.12 (2H, m, H-8, H-8’)] (Figure 88). In 
comparison with the ECD pattern and optical rotation in the literature, the structure 
of 62 was assigned as (-)-pinoresinol (Ren et al. 2015). 
 







4.10. Compound 63 
 
The molecular composition of compound 63 was indicated as C10H10O4 by ESIMS. 
Based on the 1H and 13C NMR spectra, the presence of trans-oriented olefinic group, 
1,2,4-trisubstituted aromatic ring, and carboxylic acid moiety was suggested, whose 
signals were observed at δH 7.58 (1H, d, J = 15.8 Hz, H-7), 6.30 (1H, d, J = 15.8 Hz, 
H-8), 7.17 (1H, s, H-2), 7.05 (1H, d, J = 8.1 Hz, H-6), 6.80 (1H, d, J = 8.1 Hz, H-5), 
and δC 171.9 (C-9) (Figure 89). The structure of 63 was identified as trans-ferulic 
acid (Nishanbaev et al. 2015). 
 












4.11. Compound 64 
 
Compound 64 had the molecular formula of C9H7NO, which was determined by 
ESIMS (m/z 146 [M+H]+). In the 1H NMR spectrum, the signals of aldehyde group 
and disubstituted aromatic ring were detected at δH 9.86 (1H, s, 3-CHO), 8.13 (1H, 
d, J = 7.9 Hz, H-4), 7.45 (1H, d, J = 7.9 Hz, H-7), 7.25 (1H, t, J = 7.9 Hz, H-6), and 
7.21 (1H, t, J = 7.9 Hz, H-5) (Figure 90). The olefinic signals were also observed at 
δH 8.07 (1H, s, H-2), δc 138.3 (C-2), and 118.8 (C-3). The subunits were assembled 
base on the HMBC correlations of H-7 with C-5 and C-9, H-4 with C-3, C-6, and C-
8, and H-2 with C-3, C-8, C-9, and 3-CHO. In consideration of the ESIMS peak (m/z 
146 [M+H]+) and chemical shift of C-2 (δc 138.3) and C-8 (δc 137.6), the existence 
of heteroatom N was inferred and it was located between C-2 and C-8. Taken 
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Chapter 5. Remark 
 
5.1. Acyl migration 
 
The monoacylkhellactones 17-20 were isolated from same fraction, H39. 
Because of the migration between the hydroxyl and senecioyl groups at 3’- 
and 4’-positions, interconversion between 17 and 19 and between 18 and 20 
was observed (Figures 93 and 94). The suggested mechanism of acyl 
migration was shown in Scheme 1. Seven-membered ring hydrogen bonding 
between hydroxyl proton and carbonyl oxygen might help the migration of 
substituent without inversion at 3’- or 4’-position. About 4 days after isolation, 
the acyl migration reached equilibrium. The migration of the 3’-substituent to 
the 4’- position was more dominant than vice versa. In this study, a few 
monoacylkhellactones were isolated along with their positional isomers, such 
as 13 and 14, 17 and 19, 18 and 20, 24 and 29, and 30 and 33. 
 
Figure 93. Acyl migration of 17 and 19 over time 
(Column: CHIRALPAK IC (4.6 mm x 250 mm, 5 μm); Mobile phase: 100% 




















Figure 94. Acyl migration of 18 and 20 over time 
(Column: CHIRALPAK IC (4.6 mm x 250 mm, 5 μm); Mobile phase: 100% 
methanol; Flow rate: 1.0 ml/min; UV detection: 327 nm) 
 
 


























5.2. MS fragmentation 
 
In the MS spectrum of khellactone esters, the cleavage at the 4’-position 
was observed, which was detected as a major fragmentation (Scheme 2). The 
MS fragmentation commonly occurred at 4’-position, but the fragment peak 
without a 3’-ester moiety was detected as a small peak or undetectable 
depending on the ionization method or energy. The MS fragmentation peaks 
of 1-20 revealed the position of substituents, which corresponded with the 
result of HMBC analysis (Table 1). Based on the MS fragmentation, the 














Table 1. Major ions in the mass spectra of compounds 1-20 
compound molecular formula (m.w.) [M]+ or [M+H]+ or [M+Na]+ [M-R2OH+H]+ [M-R2OH-(R1-H) +H]+ [M-R2OH-(OR1-H) +H]+ Others 
1a C23H28O7 (416.46) 417 (4) [M+H]+ 315 (100) 245 (24) 229 (21) 329 (12) [M-R1OH+H]+, 445 (14) [M+C2H5]+ 
2b C21H22O7 (386.40) 409 (60) [M+Na]+ 287 (5) 245 (2)  425 (100) [M+K]+, 795 (14) [2M+Na]+, 811 (16) [2M+K]+ 
3a C23H28O7 (416.46) 417 (2) [M+H]+ 329 (100) 245 (14) 229 (19) 315 (32) [M-R1OH+H]+, 445 (11) [M+C2H5]+ 
4a C24H28O7 (428.47) 429 (2) [M+H]+ 329 (100) 245 (8) 229 (10) 327 (40) [M-R1OH+H]+, 457 (9) [M+C2H5]+ 
5a C24H28O7 (428.47) 429 (5) [M+H]+ 327 (100) 245 (12) 229 (20) 329 (60) [M-R1OH+H]+, 457 (19) [M+C2H5]+ 
6a C23H28O7 (416.46) 417 (2) [M+H]+ 315 (100) 245 (13) 229 (13) 445 (7) [M+C2H5]+ 
7b C24H28O7 (428.47) 451 (100) [M+Na]+ 329 (6)   879 (75) [2M+Na]+ 
8b C23H28O7 (416.46) 439 (100) [M+Na]+ 315 (4)   855 (13) [2M+Na]+ 
9b C24H28O7 (428.47) 451 (100) [M+Na]+ 329 (19)   879 (5) [2M+Na]+ 
10a C21H24O8 (404.41) 405 (2) [M+H]+ 287 (100) 245 (16) 229 (14) 433 (3) [M+C2H5]+ 
11a C21H24O8 (404.41) 404 (4) [M]+ 287 (27) 245 (47) 229 (100)  
12b C21H24O7 (388.41) 411 (100) [M+Na]+ 287 (25) 245 (12)  799 (14) [2M+Na]+ 
13b C19H22O6 (346.37) 369 (100) [M+Na]+ 329 (3) 245 (3)   
14b C19H22O6 (346.37) 369 (100) [M+Na]+ 245 (6)   715 (9) [2M+Na]+ 
15b C20H24O6 (360.40) 383 (54) [M+Na]+ 329 (100)    
16a C19H20O6 (344.36) 345 (12) [M+H]+ 245 (100)  229 (21) 327 (25) [M-R1OH+H]+, 373 (10) [M+C2H5]+ 
17b C19H20O6 (344.36) 367 (41) [M+Na]+ 245 (100)   711 (80) [2M+Na]+ 
18b C19H20O6 (344.36) 367 (100) [M+Na]+ 245 (5)   711 (14) [2M+Na]+ 
19b C19H20O6 (344.36) 367 (18) [M+Na]+ 327 (100)   711 (51) [2M+Na]+ 
20b C19H20O6 (344.36) 367 (30) [M+Na]+ 327 (100)   711 (49) [2M+Na]+ 
a Data were acquired by CIMS 
b Data were acquired by ESIMS 





Chapter 6. Bioactivity of the Isolated Compounds 
 
6.1. NO production inhibitory activity of isolated compounds 
 
As mentioned in introduction section, the roots of Peucedanum japonicum were 
used as a traditional cold medicine. To find anti-inflammatory compound and 
identify structure and activity relationship, NO production inhibitory activity was 
evaluated in LPS-stimulated RAW264.7 cells. Compounds 1, 3-6, 22, 31, and 36-38 
displayed significant inhibitory effects (IC50 < 20 μΜ) without cytotoxicity, while 
compounds 2, 10, 25-28, 32, 34, 40-44, 47-48, 50-51, and 53-59 showed IC50 > 50 
μΜ. As a result, it was revealed that the isobutyryl, senecioyl, 2-methylbutyryl, and 
isovaleryl groups at 3’ position played important role for NO production inhibitory 
activity. 
 
Table 2. Inhibitory activity of isolated compounds on NO production in LPS-
stimulated RAW 264.7 cells 
compound IC50 (μΜ)
a compound IC50 (μΜ)
a 
1 11.1 ± 1.8 35 24.1 ± 2.6 
3 3.4 ± 2.6 36 12.0 ± 0.5 
4 13.9 ± 9.4 37 11.5 ± 2.6 
5 19.5 ± 5.5 38 21.7 ± 5.0 
6 18.6 ± 5.2 45 24.7 ± 6.0 
7 35.7 ± 8.5 46 45.5 ± 2.1 
12 35.6 ± 4.7 49 23.4 ± 5.8 
21 28.0 ± 1.8 52 44.6 ± 8.2 
22 8.1 ± 4.0 L-NAMEb 34.6 ± 9.3 
31 12.0 ± 2.5   
a Values were expressed as the means ± SD from triplicate experiments. 








7.1.1. Plant material 
 
Roots of Peucedanum japonicum were collected in the Taean-gun, 
Chungcheongnam-do, Korea, in November 2012. It was identified by Prof. Je Hyun 
Lee, College of Oriental medicine, Dongguk university. A voucher specimen (Ref: 
SNUPH 2012-02/KOR) is deposited in the herbarium of Seoul National University 




Column chromatography was carried out with Merck silica gel 60 (40-63 μm). 
Analytical TLC was performed with Merck silica gel 60 F254 precoated TLC plate 
and Merck RP-18 F254s precoated TLC plate. Dae Jung first grade solvents were used 
for extraction, fractionation, and isolation. Fisher HPLC grade solvents were used 
for MPLC and HPLC. To prepare MTPA derivatives, pyridine-d5 (Cambridge 
Isotope Laboratories, Inc.), (R)-(-)- and (S)-(+)-MTPA-Cl (Fluka), and DMAP 




Optical rotations were obtained using JASCO P-2000 polarimeter. UV spectra were 
acquired on Perkin Elmer Lambda 25 UV/Vis spectrophotometer. CD and UV 
spectra were recorded by an Applied photophysics Chirascan-plus CD spectrometer. 
IR spectra were measured on JASCO FT/IR-4200 spectrophotometer. NMR spectra 
were obtained using a Bruker AVANCE digital 400 or 500 spectrometer or JEOL 
JNM-ECA 600 spectrometer or Bruker AVANCE III HD 800 spectrometer with a 5-




a JEOL JMS 700 Spectrometer. High-resolution and low-resolution ESIMS were 
acquired using AB SCIEX Q-TOF 5600 mass spectrometer or Agilent Technologies 
6130 Quadrupole LC/MS spectrometer equipped with Agilent Technologies 1260 
Infinity LC system and INNO C18 column (4.6 × 150 mm, S-5 μm, 12 nm). The 
MPLC was conducted with Teledyne Isco Combi Flash Companion and Grace 
Reveleris C18 Reversed-Phase 120 g Cartridge. HPLC was carried out with Gilson 
321 pump, Gilson UV/VIS 151 detector, and YMC Hydrosphere C18 column (20 × 
250 mm, S-5 μm, 12 nm) or INNO C18 column (20 × 250 mm, S-5 μm, 12 nm) or 
YMC J’sphere ODS H80 column (10 × 250 mm, S-4 μm, 8 nm) or INNO C18 
column (10 × 250 mm, S-5 μm, 12 nm) or DAICEL CHIRALPAK IC column (4.6 × 
































7.2. Extraction and fractionation of P. japonicum  
 
Peucedanum japonicum roots (30.0 kg) were extracted with 100% MeOH (200 min 
x 3 with 45.5 L x 3) in an ultrasonic apparatus. After removing the solvent under 
reduced pressure, MeOH extract (2.7 kg, yield: 8.9%) was successively fractionated 
with n-hexane (454.2 g, yield: 16.9%), CHCl3 (87.9 g, yield: 3.3%), EtOAc (19.9 g, 
yield: 0.7%), and n-BuOH (97.5 g, yield: 3.6%).  
 
 














7.3. Isolation of compounds from n-hexane and CHCl3 fr
actions 
 
Part of the n-hexane fraction (406.0 g) was subjected to silica gel column 
chromatography (CC, 34 x 15.3 cm) with step gradient mixtures of n-hexane-EtOAc 
(95:5 → 0:100) to obtain fifty one fractions (H1~H51). Fraction H24 (7.5 g) was 
further purified by RP-MPLC (20 ml/min) with MeOH-H2O (75:25) to afford 
compound 46 (17.8 mg). Fraction H29 (3.5 g) eluted by MeOH-H2O (70:30) mostly 
yielded compound 55 (257.7 mg) by RP-MPLC (40 ml/min). Fraction H32 (5.3 g) 
was separated on RP-MPLC eluted with MeOH-H2O (75:25, 20 ml/min) to give 
sixteen subfractions (H32-1~H-32-16). Compounds 38 (8.0 mg, tR = 23.4 min) and 
59 (1.4 mg, tR = 17.0 min) was isolated from H32-3 using RP-HPLC (CH3CN-H2O, 
75:25, 5 ml/min). H32-4 was applied to RP-HPLC (CH3CN-H2O, 75:25, 5 ml/min) 
to acquire compound 15 (0.8 mg, tR = 26.9 min) and sub-fration H32-4-2. Compound 
39 (0.3 mg, tR = 6.0 min) was purified from subfration H32-4-2 by chiral selective 
column with MeOH (1 ml/min). H32-5 was separated by RP-HPLC (CH3CN-H2O, 
75:25, 5 ml/min) to obtain seven sub-frations (H32-5-1~H32-5-7). Compounds 1 
(15.1 mg, tR = 6.3 min), 3 (24.0 mg, tR = 6.0 min), 6 (4.7 mg, tR = 5.5 min), and sub-
fration (H32-5-5-4) were acquired from H32-5-5 using chiral selective HPLC (1 
ml/min) with MeOH. H32-5-5-4 was purified with chiral selective HPLC (1 ml/min, 
MeOH) to give 8 (0.6 mg, tR = 6.6 min). Compound 9 (2.2 mg, tR =41.6 min) was 
obtained from H32-6 applying RP-HPLC (CH3CN-H2O, 75:25, 5 ml/min). Fraction 
H34 (45.2 g) was subjected to RP-MPLC (MeOH-H2O, 70:30, 40 ml/min) to yield 
thirteen subfractions (H34-1~H-34-13). H34-7 was purified by RP-HPLC (CH3CN-
H2O, 75:25, 7 ml/min) to give compounds 7 (11.1 mg, tR = 37.2 min), 32 (53.1 mg, 
tR = 31.9 min), and subfrations (H34-7-2M, 2, 3, 4). Compound 21 (2.8 mg, tR = 28.5 
min) was acquired by RP-HPLC (CH3CN-H2O, 75:25, 7 ml/min) from H34-7-2M, 
while 35 (8.7 mg, tR = 44.5 min) and 5 (2.1 mg, tR = 45.8 min) were isolated from 
H34-7-2 and H34-7-4, respectively, using CH3CN-H2O (70:30). Compounds 4 (3.5 
mg, tR = 5.5 min) and 23 (0.9 mg, tR = 5.9 min) were provided from subfraction H34-
7-3 by chiral selective HPLC with MeOH (1 ml/min). H34-9 was applied to RP-




min), 36 (96.2 mg, tR = 28.7 min), 37 (106.6 mg, tR = 29.7 min) and 49 (4.1 mg, tR = 
17.3 min). Fraction H35 (14.7 g) was subjected to silica CC with n-hexane-EtOAc-
MeOH (60:4:1) followed by RP-HPLC (CH3CN-H2O, 80:20, 5 ml/min) to provide 
compounds 22 (79.2 mg, tR = 31.0 min), 34 (9.7 mg, tR = 34.3 min), and sub-frations 
H35-11-1, 2. Semi-preparative HPLC was performed on ODS to isolate compounds 
2 (2.8 mg, tR = 27.4 min), 25 (168.9 mg, tR = 28.2 min), and 26 (2.8 mg, tR = 25.6 
min) from H35-11-1 with CH3CN-H2O (65:35, 7 ml/min) and 12 (109.6 mg, tR = 
24.5 min) and 27 (2.3 mg, tR = 24.0 min) from H35-11-2 with CH3CN-H2O (80:20, 
5 ml/min), respectively. Fraction H37 (5.8 g) was applied to RP-MPLC using 
MeOH-H2O (55:45, 15 ml/min) followed by RP-HPLC (CH3CN-H2O, 55:45, 5 
ml/min) to obtain subfrations (H37-9-1, 4). Chiral selective HPLC was performed 
using MeOH to give compounds 30 (1.0 mg, tR = 4.7 min) and 33 (0.6 mg, tR = 5.5 
min) from H37-9-1, and compounds 13 (6.7 mg, tR = 5.4 min) and 14 (21.7 mg, tR = 
4.7 min) from H37-9-4. Fraction H39 (1,7 g) was subjected to RP-HPLC eluting 
with CH3CN-H2O (55:45, 5 ml/min) to acquire compounds 16 (2.5 mg, tR = 37.8 
min), 40 (11.4 mg, tR = 34.6 min), and enantiomeric mixtures E1 (8.1 mg, tR = 36.6 
min), E2 (7.2 mg, tR = 39.6 min). Enantioseparation was carried out with chiral 
column (MeOH, 1 ml/min) to attain compounds 17 (1.0 mg, tR = 4.5 min) and 18 
(0.5 mg, tR = 5.9 min) from E1, 19 (0.8 mg, tR = 6.3 min) and 20 (0.5 mg, tR = 5.3 
min) from E2. Fraction H41~43 (3.7 g) was subjected to RP-MPLC eluting with 
MeOH-H2O (55:45, 10 ml/min) to yield ten sub-fractions (H41~43-1~H41~43-10). 
Subfraction H41~43-2 was applied to RP-HPLC (CH3CN-H2O, 40:60, 5 ml/min) to 
isolate compounds 28 (8.7 mg, tR = 21.5 min), 51 (2.4 mg, tR = 20.3 min), 52 (1.8 
mg, tR = 26.5 min), 62 (6.0 mg, tR = 27.4 min), and 64 (4.1 mg, tR = 23.6 min). Eluting 
with CH3CN-H2O (45:55), HPLC (5 ml/min) was carried out to obtain 53 (5.3 mg, 
tR = 32.5 min) and 54 (4.1 mg, tR = 29.2 min) from H41~43-4 and 10 (3.6 mg, tR = 
50.9 min), 45 (5.0 mg, tR = 39.6 min), 48 (9.7 mg, tR = 47.5 min), and 61 (1.4 mg, tR 
= 43.4 min) from H41~43-7. Fraction 45 (4.1 g) was separated by RP-MPLC 
(MeOH-H2O, 50:50, 10 ml/min) followed by ODS HPLC (5 ml/min) employing 
CH3CN-H2O (35:65) as eluent to acquire 50 (1.1 mg, tR = 24.7 min) and 60 (2.0 mg, 
tR = 33.5 min). Fraction 49 (6.0 g) was purified by RP-HPLC (5 ml/min) after 




min) and 58 (6.3 mg, tR = 16.2 min) from subfraction H49-2 with CH3CN-H2O 
(20:80), 56 (8.7 mg, tR = 30.2 min) and 63 (5.1 mg, tR = 33.6 min) from subfraction 
H49-3 with CH3CN-H2O (25:75). 
The CHCl3 fraction was applied to silica CC (64 x 15.3 cm) with increasingly polar 
mixtures of n-hexane-EtOAc (85:15 → 0:100) to yield thirty-six fractions (C1~C36). 
Fraction C20~22 (4.8 g) was separated by MPLC (20 ml/min) on ODS eluting with 
MeOH-H2O (50:50) to attain sixteen subfractions (C20~22-1~C20~22-16). 
Subfraction C20~22-4 was applied to HPLC (5 ml/min) over ODS using CH3CN-
H2O (40:60) to acquire 41 (5.3 mg, tR = 38.5 min), 42 (2.9 mg, tR = 43.8 min), 43 
(7.9 mg, tR = 45.9 min), and subfraction C20~22-4-3. Sub-fraction C20~22-4-3 was 
further purified by RP-HPLC (CH3CN-H2O, 40:60, 5 ml/min) to give 44 (2.3 mg, tR 
= 25.6 min). Subfraction C20~22-5 was chromatographed by HPLC (CH3CN-H2O, 
40:60, 5 ml/min) over ODS followed by RP-HPLC (CH3CN-H2O, 30:70, 5 ml/min) 
to obtain 24 (1.0 mg, tR = 70.0 min) and 29 (2.6 mg, tR = 68.4 min). Compound 47 
(5.5 mg, tR = 40.8 min) was yielded from C20~22-11 by RP-HPLC (CH3CN-H2O, 
45:55, 5 ml/min). C20~22-12 was subjected to RP-HPLC (CH3CN-H2O, 45:55, 5 
ml/min) to yield seven subfractions (C20~22-12-1~C20~22-12-7). Compound 11 
(0.8 mg, tR = 31.5 min) was isolated from C20~22-12-7 by semi-preparative RP-







































7.4. Spectroscopic and spectrometric data of isolated com
pounds  
 
7.4.1. (3’S,4’S)-3'-O-isobutyryl-4'-O-(2-methylbutyryl)khellactone (1) 
Colorless needles  
C23H28O7 
[α]20D +1.4 (c 0.1, MeOH) 
UV (MeOH) λmax (log ε) 226 (3.52), 248 (3.12), 259 (2.99), 300 (3.45), 325 (3.63) 
nm 
CD (MeOH) λmax (Δε) 224 (-3.73), 244 (+0.92), 256 (+0.73), 323 (-0.87) nm 
1H NMR data (400 MHz, CDCl3): See Table 3 
13C NMR data (100 MHz, CDCl3): See Table 9 
CIMS m/z 417 [M+H]+;  
HRCIMS m/z 417.1912 [M+H]+ (calcd for C23H29O7, 417.1913) 
 
7.4.2. (3’S,4’S)-3'-O-acetyl-4'-O-senecioylkhellactone (2) 
Colorless needles  
C21H22O7 
[α]20D -5.5 (c 1.0, MeOH)  
UV (MeOH) λmax (log ε) 221 (4.24), 247 (3.62), 257 (3.48), 296 (3.68), 326 (3.86) 
nm 
CD (MeOH) λmax (Δε) 226 (-17.00), 245 (+2.86), 255 (+2.46), 319 (-2.44) nm 
1H NMR data (400 MHz, CDCl3): See Table 3 
13C NMR data (100 MHz, CDCl3): See Table 9 
HRESIMS m/z 409.1258 [M+Na]+ (calcd for C21H22O7Na, 409.1258) 
 
7.4.3. (3’S,4’S)-4'-O-isobutyryl-3'-O-(2-methylbutyryl)khellactone (3)  
Colorless needles  
C23H28O7 
[α]20D +51.8 (c 0.1, MeOH)  





CD (MeOH) λmax (Δε) 225 (-19.43), 245 (+3.31), 256 (+2.63), 323 (-4.16) nm 
IR νmax 2974, 2938, 2875, 1745, 1608, 1491, 1220, 1147, 772 cm-1  
1H NMR data (400 MHz, CDCl3): See Table 3 
13C NMR data (100 MHz, CDCl3): See Table 9 
CIMS m/z 417 [M+H]+ 
HRCIMS m/z 417.1910 ([M+H]+, calcd for C23H29O7:417.1913) 
 
7.4.4. (3’S,4’S)-3'-O-(2-methylbutyryl)-4'-O-senecioylkhellactone (4)  
White amorphous powder 
C24H28O7 
[α]20D -20.4 (c 0.1, MeOH) 
UV (MeOH) λmax (log ε) 220 (4.44), 248 (3.77), 258 (3.63), 299 (3.93), 324 (4.12) 
nm 
CD (MeOH) λmax (Δε) 225 (-29.78), 246 (+4.94), 256 (+4.21), 326 (-5.38) nm 
IR νmax 2976, 2938, 2877, 1741, 1608, 1491, 1221, 1144, 1074, 772 cm-1 
1H NMR data (400 MHz, CDCl3): See Table 3 
13C NMR data (100 MHz, CDCl3): See Table 9 
CIMS m/z 429 [M+H]+ 
HRCIMS m/z 429.1909 [M+H]+ (calcd for C24H29O7, 429.1913) 
 
7.4.5. (3’S,4’S)-4'-O-(2-methylbutyryl)-3'-O-senecioylkhellactone (5)  
White amorphous powder 
C24H28O7 
[α]20D +6.4 (c 0.1, MeOH) 
UV (MeOH) λmax (log ε) 226 (3.52), 248 (3.12), 258 (3.04), 300 (3.45), 322 (3.64) 
nm 
CD (MeOH) λmax (Δε) 225 (-17.32), 246 (+3.05), 256 (+2.14), 323 (-4.93) nm 
IR νmax 2976, 2934, 1747, 1608, 1220, 1146, 772 cm-1 
1H NMR data (600 MHz, CDCl3): See Table 3 
13C NMR data (150 MHz, CDCl3): See Table 9 
CIMS m/z 429 [M+H]+ 





7.4.6. (3’S,4’S)-3'-O-isobutyryl-4'-O-isovalerylkhellactone (6)  
White amorphous powder 
C23H28O7 
[α]20D -8.9 (c 0.1, MeOH) 
UV (MeOH) λmax (log ε) 221 (4.05), 248 (3.51), 258 (3.43), 298 (3.86), 325 (4.05) 
nm 
CD (MeOH) λmax (Δε) 224 (-8.79), 245 (+2.53), 255 (+1.94), 323 (-1.80) nm 
1H NMR data (400 MHz, CDCl3): See Table 3 
13C NMR data (100 MHz, CDCl3): See Table 9 
CIMS m/z 417 [M+H]+ 
HRCIMS m/z 417.1917 [M+H]+ (calcd for C23H29O7, 417.1913) 
 
7.4.7. (3’S,4’S)-4'-O-angeloyl-3'-O-(2-methylbutyryl)khellactone (7) 
White amorphous powder 
C24H28O7 
[α]20D -58.7 (c 0.1, MeOH) 
UV (MeOH) λmax (log ε) 221 (4.30), 249 (3.65), 258 (3.57), 299 (3.93), 325 (4.11) 
nm 
CD (MeOH) λmax (Δε) 226 (-7.15), 246 (+1.36), 254 (+1.24), 318 (-1.25) nm 
1H NMR data (500 MHz, CDCl3): See Table 3 
13C NMR data (125 MHz, CDCl3): See Table 9 
HRESIMS m/z 451.1729 [M+Na]+ (calcd for C24H28O7Na, 451.1727) 
 
7.4.8. (3’S,4’S)-3'-O-butyryl-4'-O-(2-methylbutyryl)khellactone (8) 
Colorless needles 
C23H28O7 
[α]20D +7.0 (c 0.1, MeOH) 
UV (MeOH) λmax (log ε) 226 (3.60), 247 (3.26), 258 (3.17), 299 (3.57), 325 (3.75) 
nm 
CD (MeOH) λmax (Δε) 224 (-4.58), 243 (+1.03), 257 (+0.90), 326 (-1.04) nm 




13C NMR data (200 MHz, CDCl3): See Table 9 
HRESIMS m/z 439.1719 [M+Na]+ (calcd for C23H28O7Na, 439.1727) 
 
7.4.9. (3’S,4’S)-4'-O-angeloyl-3'-O-isovalerylkhellactone (9)  
White amorphous powder;  
C24H28O7  
[α]20D -40.0 (c 0.1, MeOH) 
UV (MeOH) λmax (log ε) 221 (4.29), 247 (3.70), 258 (3.58), 298 (3.84), 325 (4.01) 
nm 
CD (MeOH) λmax (Δε) 225 (-19.19), 246 (+2.61), 256 (+2.66), 326 (-2.57) nm 
1H NMR data (800 MHz, CDCl3): See Table 4 
13C NMR data (200 MHz, CDCl3): See Table 9 
HRESIMS m/z 451.1724 [M+Na]+ (calcd for C24H28O7Na, 451.1727) 
 
7.4.10. (3’S,4’S)-3'-O-acetyl-4'-O-(3-hydroxyisovaleryl)khellactone (10)  
White amorphous powder 
C21H24O8  
[α]20D +23.3 (c 0.3, CHCl3) 
UV (MeOH) λmax (log ε) 222 (4.03), 247 (3.58), 258 (3.47), 299 (3.85), 325 (4.02) 
nm 
CD (MeOH) λmax (Δε) 224 (-7.73), 245 (+2.32), 255 (+1.72), 322 (-1.43) nm 
1H NMR data (400 MHz, CDCl3): See Table 4 
13C NMR data (100 MHz, CDCl3): See Table 9 
CIMS m/z 405 [M+H]+ 
HRCIMS m/z 405.1548 [M+H]+ (calcd for C21H25O8, 405.1549) 
 
7.4.11. (3’S,4’S)-3'-O-acetyl-4'-O-(3-hydroxy-2-methylbutyryl)khellactone (11) 
White amorphous powder 
C21H24O8  
[α]20D -3.2 (c 0.1, MeOH) 





CD (MeOH) λmax (Δε) 224 (-8.32), 244 (+1.98), 255 (+1.52), 321 (-1.44) nm 
1H NMR data (600 MHz, CDCl3): See Table 4 
13C NMR data (150 MHz, CDCl3): See Table 10 
CIMS m/z 404 [M]+ 
HRCIMS m/z 404.1466 [M]+ (calcd for C21H24O8, 404.1471) 
 
7.4.12. (3’S,4’S)-3'-O-acetyl-4'-O-(2-methylbutyryl)khellactone (12)  
White amorphous powder 
C21H24O7  
[α]20D +5.1 (c 2.0, CHCl3) 
UV (MeOH) λmax (log ε) 221 (3.34), 249 (2.73), 259 (2.61), 299 (3.03), 325 (3.23) 
nm 
CD (MeOH) λmax (Δε) 224 (-11.8), 244 (+3.16), 256 (+2.24), 324 (-3.03) nm 
1H NMR data (400 MHz, CDCl3): See Table 4 
13C NMR data (100 MHz, CDCl3): See Table 10 
HRESIMS m/z 411.1400 [M+Na]+ (calcd for C21H24O7Na, 411.1414) 
 
7.4.13. (3’S,4’S)-3'-O-(2-methylbutyryl)khellactone (13)  
White amorphous powder  
C19H22O6  
[α]20D -2.8 (c 1.0, MeOH) 
UV (MeOH) λmax (log ε) 222 (4.15), 248 (3.58), 259 (3.50), 298 (3.97), 325 (4.20) 
nm 
CD (MeOH) λmax (Δε) 224 (-6.05), 235 (+1.58), 258 (+0.67), 328 (-2.16) nm 
1H NMR data (800 MHz, CDCl3): See Table 4 
13C NMR data (200 MHz, CDCl3): See Table 10 
HRESIMS m/z 369.1309 [M+Na]+ (calcd for C19H22O6Na, 369.1309) 
 
7.4.14. (3’S,4’S)-4'-O-(2-methylbutyryl)khellactone (14) 
White amorphous powder 
C19H22O6  




UV (MeOH) λmax (log ε) 223 (4.17), 249 (3.66), 259 (3.60), 298 (4.03), 327 (4.25) 
nm 
CD (MeOH) λmax (Δε) 225 (-4.15), 243 (+0.68), 257 (+0.53), 318 (-2.01) nm 
1H NMR data (400 MHz, CDCl3): See Table 4 
13C NMR data (100 MHz, CDCl3): See Table 10 
HRESIMS m/z 369.1312 [M+Na]+ (calcd for C19H22O6Na, 369.1309) 
 
7.4.15. (3’S,4’S)-4'-O-methyl-3'-O-(2-methylbutyryl)khellactone (15) 
White amorphous powder 
C20H24O6  
[α]20D +4.2 (c 0.1, MeOH) 
UV (MeOH) λmax (log ε) 220 (3.66), 247 (3.17), 259 (3.09), 300 (3.26), 326 (3.39) 
nm 
CD (MeOH) λmax (Δε) 223 (-1.16), 248 (+0.15), 259 (+0.13), 329 (-0.33) nm 
1H NMR data (800 MHz, CDCl3): See Table 4 
13C NMR data (200 MHz, CDCl3): See Table 10 
HRESIMS m/z 383.1452 [M+Na]+ (calcd for C20H24O6Na, 383.1465) 
 
7.4.16. (3’S,4’R)-4'-O-senecioylkhellactone (16)  
White amorphous powder 
C19H20O6  
[α]20D +81.1 (c 0.3, CHCl3) 
UV (MeOH) λmax (log ε) 220 (4.38), 248 (3.95), 259 (3.76), 298 (3.88), 328 (4.04) 
nm 
CD (MeOH) λmax (Δε) 226 (+18.91), 247 (-3.39), 256 (-2.86), 324 (+2.57) nm 
1H NMR data (400 MHz, CDCl3): See Table 4 
13C NMR data (100 MHz, CDCl3): See Table 10 
CIMS m/z 345 [M+H]+ 
HRCIMS m/z 345.1335 [M+H]+ (calcd for C19H21O6, 345.1338) 
 
7.4.17. (3’S,4’S)-4'-O-senecioylkhellactone (17)  





[α]20D -52.3 (c 0.1, MeOH) 
UV (MeOH) λmax (log ε) 222 (4.28), 249 (3.60), 259 (3.49), 301 (3.78), 328 (3.98) 
nm 
CD (MeOH) λmax (Δε) 226 (-6.38), 247 (+0.44), 255 (+0.33), 324 (-1.75) nm 
1H NMR data (600 MHz, CDCl3): See Table 5 
13C NMR data (150 MHz, CDCl3): See Table 10 
ESIMS m/z 367 [M+Na]+ 
 
7.4.18. (3’R,4’R)-4'-O-senecioylkhellactone (18) 
White amorphous powder 
C19H20O6  
[α]20D +38.8 (c 0.1, MeOH) 
UV (MeOH) λmax (log ε) 221 (4.13), 248 (3.47), 258 (3.37), 297 (3.60), 328 (3.82) 
nm 
CD (MeOH) λmax (Δε) 226 (+11.74), 248 (-2.48), 257 (-2.29), 326 (+2.31) nm 
1H NMR data (800 MHz, CDCl3): See Table 5 
13C NMR data (200 MHz, CDCl3): See Table 10 
HRESIMS m/z 367.1144 [M+Na]+ (calcd for C19H20O6Na, 367.1152) 
 
7.4.19. (3’S,4’S)-3'-O-senecioylkhellactone (19)  
White amorphous powder 
C19H20O6  
[α]20D +23.8 (c 0.1, MeOH) 
UV (MeOH) λmax (log ε) 222 (4.29), 248 (3.54), 259 (3.37), 298 (3.77), 326 (4.00) 
nm 
CD (MeOH) λmax (Δε) 226 (-4.31), 246 (+1.25), 257 (+1.63), 323 (-1.25) nm 
1H NMR data (600 MHz, CDCl3): See Table 5 
13C NMR data (150 MHz, CDCl3): See Table 10 
ESIMS m/z 367 [M+Na]+ 
 




White amorphous powder 
C19H20O6  
[α]20D -2.2 (c 0.1, MeOH) 
UV (MeOH) λmax (log ε) 223 (4.10), 247 (3.40), 259 (3.20), 296 (3.57), 327 (3.81) 
nm 
CD (MeOH) λmax (Δε) 224 (+0.78), 233 (-1.06), 257 (-0.36), 333 (+0.53) nm 
1H NMR data (800 MHz, CDCl3): See Table 5 
13C NMR data (200 MHz, CDCl3): See Table 10 
ESIMS m/z 367 [M+Na]+ 
 
7.4.21. (3’S,4’S)- 4'-O-angeloyl-3'-O-senecioylkhellactone (21) 
White amorphous powder 
C24H26O7 
[α]20D -16.5 (c 0.1, MeOH) 
UV (MeOH) λmax (log ε) 221 (4.37), 247 (3.70), 258 (3.53), 300 (3.82), 325 (3.99) 
nm 
CD (MeOH) λmax (Δε) 226 (-17.99), 248 (+3.26), 258 (+2.73), 329 (-2.83) nm 
1H NMR data (600 MHz, CDCl3): See Table 5 
13C NMR data (150 MHz, CDCl3): See Table 11 
ESIMS m/z 853 [2M+H]+ 
 
7.4.22. (3’S,4’S)- 3',4'-di-O-senecioylkhellactone (22) 
White amorphous powder 
C24H26O7 
[α]20D -12.6 (c 2.0, CHCl3)  
UV (MeOH) λmax (log ε) 220 (4.54), 248 (3.78), 259 (3.55), 299 (3.86), 326 (4.04) 
nm 
CD (MeOH) λmax (Δε) 226 (-22.33), 248 (+5.67), 258 (+3.44), 329 (-4.31) nm 
1H NMR data (500 MHz, CDCl3): See Table 5 
13C NMR data (125 MHz, CDCl3): See Table 11 





7.4.23. (3’S,4’S)-4'-O-isovaleryl-3'-O-senecioylkhellactone (peujaponisin) (23)  
White amorphous powder 
C24H28O7 
[α]20D +10.9 (c 0.1, MeOH)  
UV (MeOH) λmax (log ε) 221 (4.26), 247 (3.59), 257 (3.46), 298 (3.78), 326 (3.97) 
nm 
CD (MeOH) λmax (Δε) 225 (-8.44), 247 (+2.94), 258 (+1.72), 328 (-2.20) nm 
1H NMR data (600 MHz, CDCl3): See Table 5 
ESIMS m/z 451 [M+Na]+ 
 
7.4.24. (3’S,4’S)-3'-O-acetylkhellactone (qianhucoumarin B) (24)  
White amorphous powder 
C16H16O6 
[α]20D -90.5 (c 0.1, MeOH) 
UV (MeOH) λmax (log ε) 221 (4.40), 248 (3.84), 259 (3.75), 299 (4.19), 328 (4.39) 
nm 
CD (MeOH) λmax (Δε) 224 (-7.12), 248 (+1.38), 257 (+1.36), 325 (-2.74) nm 
1H NMR data (300 MHz, CDCl3): See Table 5 
13C NMR data (200 MHz, CDCl3): See Table 11 
ESIMS m/z 327 [M+Na]+ 
 
7.4.25. (3’S,4’S)-3’-O-acetyl-4’-O-angeloylkhellactone (pteryxin) (25)  
White amorphous powder 
C21H22O7 
[α]20D +3.6 (c 2.0, CHCl3) 
UV (MeOH) λmax (log ε) 220 (4.26), 248 (3.62), 258 (3.50), 297 (3.85), 325 (4.05) 
nm 
CD (MeOH) λmax (Δε) 225 (-23.74), 248 (+3.59), 257 (+3.66), 323 (-2.85) nm 
1H NMR data (400 MHz, CDCl3): See Table 6 
13C NMR data (100 MHz, CDCl3): See Table 11 





7.4.26. (3’S,4’S)-3'-O-acetyl-4'-O-isobutyrylkhellactone (hyuganin D) (26)  
White amorphous powder 
C20H22O7 
[α]20D -12.0 (c 1.0, MeOH) 
UV (MeOH) λmax (log ε) 222 (3.95), 248 (3.45), 258 (3.38), 299 (3.79), 325 (3.97) 
nm 
CD (MeOH) λmax (Δε) 225 (-7.61), 247 (+1.31), 259 (+0.46), 328 (-1.75) nm 
1H NMR data (400 MHz, CDCl3): See Table 6 
13C NMR data (100 MHz, CDCl3): See Table 11 
ESIMS m/z 749 [2M+H]+ 
 
7.4.27. (3’S,4’S)-3'-O-acetyl-3'-O-isovalerylkhellactone (suksdorfin, corymbocou 
marin) (27) 
White amorphous powder 
C21H24O7 
[α]20D -2.4 (c 1.0, MeOH) 
UV (MeOH) λmax (log ε) 225 (3.64), 249 (3.19), 257 (3.17), 299 (3.50), 325 (3.67) 
nm 
CD (MeOH) λmax (Δε) 225 (-4.16), 247 (+0.55), 256 (+0.04), 329 (-1.31) nm 
1H NMR data (600 MHz, CDCl3): See Table 6 
13C NMR data (150 MHz, CDCl3): See Table 11 
ESIMS m/z 777 [2M+H]+ 
 
7.4.28. (-)-cis-khellactone (28) 
White amorphous powder 
C14H14O5 
[α]20D -39.8 (c 1.0, MeOH) 
UV (MeOH) λmax (log ε) 221 (4.14), 247 (3.58), 259 (3.51), 299 (3.89), 329 (4.13) 
nm 
CD (MeOH) λmax (Δε) 230 (+1.35), 328 (-1.66) nm 
1H NMR data (400 MHz, CD3OD): See Table 6 




ESIMS m/z 263 [M+H]+ 
 
7.4.29. (3’S,4’S)-4'-O-acetylkhellactone (qianhucoumarin C) (29)  
White amorphous powder;  
C16H16O6  
[α]20D -50.3 (c 0.1, MeOH) 
UV (MeOH) λmax (log ε) 221 (4.32), 247 (3.78), 259 (3.67), 299 (4.12), 325 (4.34) 
nm 
CD (MeOH) λmax (Δε) 224 (-5.38), 247 (+1.56), 259 (+0.75), 326 (-2.20) nm 
1H NMR data (300 MHz, CDCl3): See Table 6 
13C NMR data (200 MHz, CDCl3): See Table 11 
ESIMS m/z 305 [M+H]+ 
 
7.4.30. (3’S,4’S)-3’-hydroxy-4’-O-angeloyloxy-3’,4’-dihydroseselin (30)  
White amorphous powder 
C19H20O6  
[α]20D -87.6 (c 0.1, MeOH) 
UV (MeOH) λmax (log ε) 221 (4.17), 248 (3.53), 259 (3.42), 299 (3.79), 325 (4.01) 
nm 
CD (MeOH) λmax (Δε) 226 (-16.04), 250 (+2.25), 260 (+1.72), 328 (-2.95) nm 
1H NMR data (800 MHz, CDCl3): See Table 6 
13C NMR data (200 MHz, CDCl3): See Table 11 
ESIMS m/z 345 [M+H]+ 
 
7.4.31. (3’S,4’S)-3'-O-angeloyl-4'-O-(2-methylbutyryl)khellactone (praeruptorin F) 
(31) 
White amorphous powder 
C24H28O7  
[α]20D +16.7 (c 1.0, MeOH) 
UV (MeOH) λmax (log ε) 221 (4.32), 247 (3.67), 258 (3.52), 297 (3.88), 325 (4.07) 
nm 




1H NMR data (600 MHz, CDCl3): See Table 6 
13C NMR data (150 MHz, CDCl3): See Table 12 
ESIMS m/z 879 [2M+Na]+ 
 
7.4.32. (3’S,4’S)-3',4'-di-O-angeloylkhellactone (anomalin, praeruptorin B) (32)  
White amorphous powder 
C24H26O7  
[α]20D +58.6 (c 0.1, CHCl3) 
UV (MeOH) λmax (log ε) 221 (4.31), 247 (3.62), 258 (3.46), 297 (3.76), 324 (3.95) 
nm 
CD (MeOH) λmax (Δε) 225 (-19.68), 248 (+3.11), 257 (+3.64), 324 (-2.21) nm 
1H NMR data (400 MHz, CDCl3): See Table 6 
13C NMR data (75 MHz, CDCl3): See Table 12 
ESIMS m/z 853 [2M+H]+ 
 
7.4.33. (3’S,4’S)-3’-O-angeloyloxy-4’-hydroxy-3’,4’-dihydroseselin (33)  
White amorphous powder  
C19H20O6  
[α]20D +12.4 (c 0.1, MeOH) 
UV (MeOH) λmax (log ε) 223 (4.07), 247 (3.39), 258 (3.27), 297 (3.66), 328 (3.89) 
nm 
CD (MeOH) λmax (Δε) 227 (-7.96), 249 (+1.21), 260 (+0.84), 328 (-1.80) nm 
1H NMR data (400 MHz, CDCl3): See Table 7 
13C NMR data (100 MHz, CDCl3): See Table 12 
ESIMS m/z 345 [M+H]+ 
 
7.4.34. (3’S,4’S)-3’-O-angeloyl-4’-O-senecioylkhellactone (calipteryxin) (34) 
White amorphous powder 
C24H26O7  
[α]20D +16.6 (c 1.0, MeOH) 





CD (MeOH) λmax (Δε) 225 (-17.20), 247 (+3.66), 259 (+2.35), 325 (-2.11) nm 
1H NMR data (400 MHz, CDCl3): See Table 7 
13C NMR data (100 MHz, CDCl3): See Table 12 
ESIMS m/z 853 [2M+H]+ 
 
7.4.35. (3’S,4’S)-3'-O-isovaleryl-4'-O-senecioylkhellactone (35) 
White amorphous powder 
C24H28O7  
[α]20D -7.5 (c 10.0, MeOH) 
UV (MeOH) λmax (log ε) 222 (4.12), 247 (3.51), 257 (3.40), 299 (3.64), 323 (3.83) 
nm 
CD (MeOH) λmax (Δε) 226 (-16.52), 249 (+2.96), 258 (+2.33), 323 (-2.69) nm 
1H NMR data (600 MHz, CDCl3): See Table 7 
13C NMR data (150 MHz, CDCl3): See Table 12 
ESIMS m/z 857 [2M+H]+ 
 
7.4.36. (3’S,4’S)-3',4'-di-O-isovalerylkhellactone (36)  
White amorphous powder 
C24H30O7  
[α]20D -15.4 (c 1.0, MeOH) 
UV (MeOH) λmax (log ε) 220 (4.27), 247 (3.71), 258 (3.59), 296 (3.98), 325 (4.17) 
nm 
CD (MeOH) λmax (Δε) 224 (-11.90), 247 (+2.34), 257 (+1.65), 324 (-2.69) nm 
1H NMR data (300 MHz, CDCl3): See Table 7 
13C NMR data (75 MHz, CDCl3): See Table 12 
ESIMS m/z 883 [2M+Na]+ 
 
7.4.37. (3’S,4’S)-3'-O-isovaleryl-4'-O-(2-methylbutyryl)khellactone (praeruptorin H) 
(37)  
White amorphous powder 
C24H30O7  




UV (MeOH) λmax (log ε) 220 (4.20), 248 (3.66), 258 (3.57), 296 (3.91), 327 (4.12) 
nm 
CD (MeOH) λmax (Δε) 227 (-7.01), 247 (+1.46), 258 (+1.06), 326 (-2.29) nm 
1H NMR data (600 MHz, CDCl3): See Table 7 
13C NMR data (150 MHz, CDCl3): See Table 12 
ESIMS m/z 883 [2M+Na]+ 
 
7.4.38. (3’R)-O-senecioyllomatin (38) 
White amorphous powder 
C19H20O5  
[α]20D +85.9 (c 0.1, MeOH) 
UV (MeOH) λmax (log ε) 223 (4.31), 259 (3.39), 328 (3.98) nm 
CD (MeOH) λmax (Δε) 226 (+4.78), 245 (-2.19), 257 (-1.43), 326 (+3.51) nm 
1H NMR data (300 MHz, CDCl3): See Table 7 
13C NMR data (75 MHz, CDCl3): See Table 12 
ESIMS m/z 329 [M+H]+ 
 
7.4.39. (3’R)-O-isovaleroyllomatin (39)  
White amorphous powder 
C19H22O5  
[α]20D +50.4 (c 0.1, MeOH) 
UV (MeOH) λmax (log ε) 224 (3.84), 248 (3.27), 258 (3.22), 328 (3.84) nm 
CD (MeOH) λmax (Δε) 223 (+2.36), 246 (-0.40), 255 (-0.35), 325 (+1.13) nm 
1H NMR data (800 MHz, CDCl3): See Table 7 
13C NMR data (200 MHz, CDCl3): See Table 12 
ESIMS m/z 331 [M+H]+ 
 
7.4.40. (3’R,4’R)-3’,4’-di-O-acetylkhellactone (qianhucoumarin D) (40)  
White amorphous powder 
C18H18O7  
[α]20D +1.8 (c 0.1, MeOH) 





CD (MeOH) λmax (Δε) 224 (+1.77), 245 (-0.74), 254 (-0.48), 330 (+0.17) nm 
1H NMR data (500 MHz, CD3OD): See Table 7 
13C NMR data (125 MHz, CD3OD): See Table 12 
ESIMS m/z 693 [2M+H]+ 
 
7.4.41. 2’-hydroxy-3’-O-senecioylvaginol (41) 
White amorphous powder 
C19H20O7 
[α]25D +3.5 (c 0.3, CHCl3) 
UV (MeOH) λmax (log ε) 218 (4.42), 250 (3.92), 260 (3.81), 300 (3.93), 325 (4.10) 
nm 
CD (MeOH) λmax (Δε) 227 (+8.76), 246 (-1.88), 305 (-1.97) nm 
1H NMR data (500 MHz, CDCl3): See Table 8 
13C NMR data (125 MHz, CDCl3): See Table 13 
CIMS m/z 361 [M+H]+ 
HRCIMS m/z 361.1284 [M+H]+ (calcd for C19H21O7, 361.1287) 
 
7.4.42. 2’-hydroxy-3’-O-(2-methylbutyryl)vaginol (42) 
White amorphous powder 
C19H22O7 
[α]25D +61.5 (c 0.3, CHCl3)  
UV (MeOH) λmax (log ε) 219 (4.29), 250 (3.86), 261 (3.74), 301 (4.06), 325 (4.25) 
nm 
CD (MeOH) λmax (Δε) 225 (+7.08), 240 (-1.88), 306 (-2.69) nm 
1H NMR data (400 MHz, CDCl3): See Table 8 
13C NMR data (100 MHz, CDCl3): See Table 13 
CIMS m/z 363 [M+H]+ 
HRCIMS m/z 363.1450 [M+H]+ (calcd for C19H23O7, 363.1444) 
 
7.4.43. 2’-hydroxy-3’-O-isovalerylvaginol (43)  





[α]25D +4.5 (c 1.0, CHCl3) 
UV (MeOH) λmax (log ε) 219 (4.18), 250 (3.75), 261 (3.61), 300 (3.93), 325 (4.13) 
nm 
CD (MeOH) λmax (Δε) 225 (+3.59), 240 (-1.71), 305 (-2.35) nm 
1H NMR data (500 MHz, CDCl3): See Table 8 
13C NMR data (125 MHz, CDCl3): See Table 13 
CIMS m/z 363 [M+H]+ 
HRCIMS m/z 363.1448 [M+H]+ (calcd for C19H23O7, 363.1444) 
 
7.4.44. (+)-marmesin (nodakenetin) (44)  
White amorphous powder 
C14H14O4 
[α]20D +37.5 (c 0.1, MeOH) 
UV (MeOH) λmax (log ε) 227 (3.92), 261 (3.42), 301 (3.63), 335 (3.93) nm 
1H NMR (400 MHz, CD3OD) δ 7.83 (1H, d, J = 9.5 Hz, H-4), 7.39 (1H, s, H-5), 6.71 
(1H, s, H-8), 6.18 (1H, d, J = 9.5 Hz, H-3), 4.74 (1H, dd, J = 9.0, 8.4 Hz, H-2’), 3.24 
(2H, m, H-3’), 1.28 (3H, s, H-5’), 1.22 (3H, s, H-6’). 
13C NMR (100 MHz, CD3OD) δ 166.1 (C-7), 164.6 (C-2), 157.7 (C-9), 147.01 (C-
4), 128.1 (C-6), 125.8 (C-5), 114.9 (C-10), 113.0 (C-3), 99.0 (C-8), 93.3 (C-2’), 73.1 
(C-4’), 31.1 (C-3’), 26.2 (C-5’), 26.1 (C-6’). 
ESIMS m/z 247 [M+H]+ 
 
7.4.45. 9-(2-hydroxy-3-methoxy-3-methylbutoxy)bergapten (45)  
White amorphous powder 
C18H20O7 
[α]20D +21.7 (c 0.1, MeOH) 
UV (MeOH) λmax (log ε) 225 (4.17), 243 (3.91), 250 (3.90), 273 (4.00), 316 (3.84) 
nm 
1H NMR (400 MHz, CD3OD) δ 8.25 (1H, d, J = 9.8 Hz, H-4), 7.83 (1H, d, J = 2.3 
Hz, H-2’), 7.23 (1H, d, J = 2.3 Hz, H-3’), 6.29 (1H, d, J = 9.8 Hz, H-3), 4.52 (1H, 




OMe), 3.94 (1H, dd, J = 8.1, 2.5 Hz, H-2’’), 3.23 (3H, s, 3’’-OMe), 1.24 (3H, s, H-
4’’), 1.19 (3H, s, H-5’’). 
13C NMR (100 MHz, CD3OD) δ 163.5 (C-2), 152.5 (C-7), 147.8 (C-2’), 146.9 (C-5), 
145.8 (C-9), 142.3 (C-4), 129.3 (C-8), 117.1 (C-6), 114.0 (C-3), 109.5 (C-10), 107.2 
(C-3’), 78.5 (C-3’’), 77.7 (C-2’’), 77.6 (C-1’’), 62.3 (5-OMe), 50.4 (3’’-OMe), 23.0 
(C-4’’), 21.5 (C-5’’). 
ESIMS m/z 349 [M+H]+ 
 
7.4.46. isoimperatorin (46)  
White amorphous powder 
C16H14O4 
[α]20D +1.8 (c 1.0, MeOH) 
UV (MeOH) λmax (log ε) 223 (4.05), 253 (3.87), 312 (3.77) nm 
1H NMR (300 MHz, CDCl3) δ 8.14 (1H, d, J = 9.8 Hz, H-4), 7.57 (1H, d, J = 2.4 Hz, 
H-2’), 7.13 (1H, s, H-8), 6.93 (1H, dd, J = 2.4, 0.9 Hz, H-3’), 6.25 (1H, d, J = 9.8 
Hz, H-3), 5.51 (1H, t, J = 7.0 Hz, H-2’’), 4.90 (2H, d, J = 7.0 Hz, H-1’’), 1.77 (3H, 
s, H-4’’), 1.67 (3H, s, H-5’’). 
13C NMR (75 MHz, CDCl3) δ 161.3 (C-2), 158.1 (C-7), 152.6 (C-9), 148.9 (C-5), 
144.8 (C-2’), 139.8 (C-3’’), 139.6 (C-4), 119.0 (C-2’’), 114.1 (C-6), 112.5 (C-3), 
107.4 (C-10), 105.0 (C-3’), 94.2 (C-8), 69.7 (C-1’’), 25.8 (C-4’’), 18.2 (C-5’’). 
ESIMS m/z 271 [M+H]+ 
 
7.4.47. 5-(2-hydroxy-3-methoxy-3-methylbutoxy)psoralen (47) 
White amorphous powder 
C17H18O6 
[α]20D +23.8 (c 0.1, MeOH) 
UV (MeOH) λmax (log ε) 224 (4.29), 252 (4.14), 312 (4.05) nm 
1H NMR (400 MHz, CDCl3) δ 8.21 (1H, d, J = 9.8 Hz, H-4), 7.58 (1H, d, J = 2.4 Hz, 
H-2’), 7.15 (1H, s, H-8), 6.98 (1H, dd, J = 2.4, 0.8 Hz, H-3’), 6.27 (1H, d, J = 9.8 
Hz, H-3), 4.55 (1H, dd, J = 10.0, 3.1 Hz, H-1’’a), 4.37 (1H, dd, J = 10.0, 7.8 Hz, H-
1’’b), 3.92 (1H, dd, J = 7.8, 3.1 Hz, H-2’’), 3.25 (3H, s, 3’’-OMe), 1.25 (3H, s, H-




13C NMR (100 MHz, CDCl3) δ 161.2 (C-2), 158.1 (C-7), 152.6 (C-9), 148.8 (C-5), 
145.0 (C-2’), 139.4 (C-4), 114.1 (C-6), 112.9 (C-3), 107.3 (C-10), 104.9 (C-3’), 94.5 
(C-8), 76.1 (C-2’’), 75.9 (C-3’’), 74.3 (C-1’’), 49.3 (3’’-OMe), 20.7 (C-4’’, C-5’’). 
ESIMS m/z 319 [M+H]+ 
 
7.4.48. 3’-O-senecioylvaginidiol ((+)-8,9-dihydro-8-(2-hydroxy propan-2-yl)-2-
oxo-2H-furo[2,3-h]chromen-9-yl-3-methylbut-2-enoate) (48) 
White amorphous powder 
C19H20O6 
[α]20D +84.4 (c 0.1, MeOH) 
UV (MeOH) λmax (log ε) 220 (4.38), 250 (3.96), 326 (4.24) nm 
CD (MeOH) λmax (Δε) 224 (-14.82), 251 (+1.93), 261 (+2.21), 321 (+4.54) nm 
1H NMR (400 MHz, CD3OD) δ 7.87 (1H, d, J = 9.6 Hz, H-4), 7.59 (1H, d, J = 8.5 
Hz, H-5), 6.98 (1H, d, J = 6.6 Hz, H-3’), 6.93 (1H, d, J = 8.5 Hz, H-6), 6.21 (1H, d, 
J = 9.6 Hz, H-3), 5.63 (1H, s, H-2’’), 4.61 (1H, d, J = 6.6 Hz, H-2’), 2.20 (3H, br s, 
H-4’’), 1.90 (3H, br s, H-5’’), 1.39 (3H, s, H-5’), 1.33 (3H, s, H-6’). 
13C NMR (100 MHz, CD3OD) δ 166.8 (C-1’’), 166.4 (C-7), 162.9 (C-2), 161.4 (C-
3’’), 153.7 (C-9), 146.7 (C-4), 133.8 (C-5), 116.9 (C-2’’), 115.6 (C-10), 115.3 (C-8), 
114.1 (C-3), 109.7 (C-6), 94.4 (C-2’), 72.7 (C-4’), 69.5 (C-3’), 28.3 (C-5’’), 27.3 (C-
5’), 27.0 (C-6’), 21.4 (C-4’’). 
ESIMS m/z 711 [2M+Na]+ 
 
7.4.49. (S)-(+)-decursin (49)  
White amorphous powder 
C19H20O5  
[α]20D +88.1 (c 0.1, MeOH) 
UV (MeOH) λmax (log ε) 221 (4.17), 261 (3.24), 296 (3.61), 331 (3.81) nm 
CD (MeOH) λmax (Δε) 215 (-5.34), 230 (+1.72), 247 (+1.08), 259 (+0.72), 329 (+0.43) 
nm 
1H NMR (300 MHz, CDCl3) δ 7.55 (1H, d, J = 9.5 Hz, H-4), 7.12 (1H, s, H-5), 6.77 
(1H, s, H-8), 6.20 (1H, d, J = 9.5 Hz, H-3), 5.64 (1H, br s, H-2’’), 5.06 (1H, t, J = 




H-4’b), 2.12 (3H, br s, H-4’’), 1.85 (3H, br s, H-5’’), 1.36 (3H, s, H-5’), 1.34 (3H, s, 
H-6’). 
13C NMR (75 MHz, CDCl3) δ 165.7 (C-1’’), 161.3 (C-2), 158.4 (C-3’’), 156.4 (C-7), 
154.1 (C-9), 143.1 (C-4), 128.6 (C-5), 115.9 (C-6), 115.5 (C-2’’), 113.2 (C-3), 112.8 
(C-10), 104.7 (C-8), 76.7 (C-2’), 69.1 (C-3’), 27.9 (C-4’), 27.5 (C-5’’), 25.0 (C-5’), 
23.2 (C-6’), 20.4 (C-4’’). 
ESIMS m/z 329 [M+H]+ 
 
7.4.50. isoarnottinin (50)  
White amorphous powder 
C14H14O4  
[α]20D +26.0 (c 0.1, MeOH) 
UV (MeOH) λmax (log ε) 263 (3.57), 328 (3.73) nm 
1H NMR (400 MHz, CD3 OD) δ 7.81 (1H, d, J = 9.4 Hz, H-4), 7.29 (1H, d, J = 8.5 
Hz, H-5), 6.80 (1H, d, J = 8.5 Hz, H-6), 6.16 (1H, d, J = 9.4 Hz, H-3), 5.53 (1H, t, J 
= 7.3 Hz, H-2’), 3.89 (2H, s, H-4’), 3.56 (2H, d, J = 7.3 Hz, H-1’), 1.87 (3H, s, H-
5’). 
13C NMR (100 MHz, CD3OD) δ 164.6 (C-2), 161.4 (C-7), 155.7 (C-9), 147.3 (C-4), 
137.5 (C-3’), 128.7 (C-5), 124.4 (C-2’), 117.2 (C-8), 114.4 (C-6), 114.1 (C-10), 
112.7 (C-3), 69.6 (C-4’), 23.1 (C-1’), 14.7 (C-5’). 
ESIMS m/z 247 [M+H]+ 
 
7.4.51. umbelliferone (51) 
White amorphous powder 
C9H6O3  
[α]20D +54.7 (c 0.1, MeOH) 
UV (MeOH) λmax (log ε) 220 (3.83), 257 (3.29), 292 (3.51), 325 (3.73) nm 
1H NMR (500 MHz, CD3OD) δ 9.74 (1H, s, 7-OH), 7.84 (1H, d, J = 9.4 Hz, H-4), 
7.44 (1H, d, J = 8.5 Hz, H-5), 6.78 (1H, dd, J = 8.5, 2.2 Hz, H-6), 6.70 (1H, d, J = 
2.2 Hz, H-8), 6.17 (1H, d, J = 9.4 Hz, H-3). 
13C NMR (125 MHz, CD3OD) δ 164.5 (C-2), 164.0 (C-7), 158.1 (C-9), 146.9 (C-4), 




ESIMS m/z 161 [M-H]- 
 
7.4.52. scoparone (52)  
White amorphous powder 
C11H10O4  
[α]20D +49.6 (c 0.1, MeOH) 
UV (MeOH) λmax (log ε) 231 (4.00), 261 (3.50), 291 (3.53), 340 (3.73) nm 
1H NMR (600 MHz, CD3OD) δ 7.86 (1H, d, J = 9.4 Hz, H-4), 7.12 (1H, s, H-5), 6.96 
(1H, s, H-8), 6.24 (1H, d, J = 9.4 Hz, H-3), 3.90 (3H, s, 7-OMe), 3.86 (3H, s, 6-
OMe). 
13C NMR (150 MHz, CD3OD) δ 162.5 (C-2), 153.5 (C-7), 150.0 (C-9), 146.8 (C-6), 
144.6 (C-4), 112.2 (C-3), 111.7 (C-10), 108.7 (C-5), 99.7 (C-8), 55.5 (6-OMe, 7-
OMe). 
ESIMS m/z 207 [M+H]+ 
 
7.4.53. tamarin (isosuberenol) (53)  
White amorphous powder 
C15H16O4  
[α]20D +3.4 (c 1.0, MeOH) 
UV (MeOH) λmax (log ε) 225 (4.28), 256 (3.65), 298 (3.93), 333 (4.19) nm 
1H NMR (600 MHz, CD3OD) δ 7.83 (1H, d, J = 9.5 Hz, H-4), 7.36 (1H, s, H-5), 6.90 
(1H, s, H-8), 6.20 (1H, d, J = 9.5 Hz, H-3), 4.76 (1H, br s, H-4’a), 4.72 (1H, br s, H-
4’b), 4.27 (1H, dd, J = 7.9, 5.7 Hz, H-2’), 3.90 (3H, s, 7-OMe), 2.93 (1H, dd, J = 
13.6, 5.7 Hz, H-1’a), 2.74 (1H, dd, J = 13.6, 7.9 Hz, H-1’b), 1.77 (3H, s, H-5’). 
13C NMR (150 MHz, CD3OD) δ 162.3 (C-2), 161.4 (C-7), 154.7 (C-9), 147.3 (C-3’), 
144.6 (C-4), 129.8 (C-5), 125.1 (C-6), 112.0 (C-10), 111.8 (C-3), 110.0 (C-4’), 98.2 
(C-8), 74.5 (C-2’), 55.2 (7-OMe), 35.7 (C-1’), 16.5 (C-5’). 
ESIMS m/z 261 [M+H]+ 
 
7.4.54. (Z)-suberenol (54) 





[α]20D +2.6 (c 1.0, MeOH) 
UV (MeOH) λmax (log ε) 227 (4.01), 256 (3.94), 298 (3.71), 335 (3.85) nm 
1H NMR (400 MHz, CD3OD) δ 7.86 (1H, d, J = 9.4 Hz, H-4), 7.59 (1H, s, H-5), 6.91 
(1H, s, H-8), 6.29 (1H, dd, J = 12.7, 0.6 Hz, H-1’), 6.23 (1H, d, J = 9.4 Hz, H-3), 
5.81 (1H, d, J = 12.7 Hz, H-2’), 3.90 (3H, s, 7-OMe), 1.26 (6H, s, H-4’, H-5’). 
13C NMR (100 MHz, CD3OD) δ 164.3 (C-2), 162.8 (C-7), 157.2 (C-9), 146.8 (C-4), 
142.5 (C-2’), 132.1 (C-5), 126.7 (C-6), 124.0 (C-1’), 114.1 (C-3), 113.7 (C-10), 
100.2 (C-8), 72.9 (C-3’), 57.4 (7-OMe), 31.5 (C-4’, C-5’). 
ESIMS m/z 261 [M+H]+ 
 
7.4.55. suberosin (55) 
White amorphous powder 
C15H16O3  
[α]20D +1.8 (c 1.0, MeOH) 
UV (MeOH) λmax (log ε) 225 (3.95), 246 (3.54), 255 (3.47), 298 (3.64), 329 (3.86) 
nm 
1H NMR (500 MHz, CDCl3) δ 7.55 (1H, d, J = 9.4 Hz, H-4), 7.11 (1H, s, H-5), 6.68 
(1H, s, H-8), 6.15 (1H, d, J = 9.4 Hz, H-3), 5.21 (1H, t, J = 7.4 Hz, H-2’), 3.82 (3H, 
s, 7-OMe), 3.23 (2H, d, J = 7.4 Hz, H-1’), 1.70 (3H, s, H-4’), 1.64 (3H, s, H-5’).  
13C NMR (125 MHz, CDCl3) δ 161.3 (C-2), 160.5 (C-7), 154.3 (C-9), 143.5 (C-4), 
133.4 (C-3’), 127.3 (C-6), 127.2 (C-5), 121.2 (C-2’), 112.5 (C-3), 111.7 (C-10), 98.3 
(C-8), 55.7 (7-OMe), 27.6 (C-1’), 25.6 (C-4’), 17.6 (C-5’). 
ESIMS m/z 245 [M+H]+ 
 
7.4.56. peucedanol (56)  
White amorphous powder 
C14H16O5  
[α]20D +2.3 (c 1.0, MeOH) 
UV (MeOH) λmax (log ε) 224 (4.15), 250 (3.58), 259 (3.50), 292 (3.77), 334 (4.12) 
nm 
1H NMR (400 MHz, CD3OD) δ 7.82 (1H, d, J = 9.4 Hz, H-4), 7.38 (1H, s, H-5), 6.71 




d, J = 14.0 Hz, H-1’a), 2.53 (1H, dd, J = 14.0, 10.4 Hz, H-1’b), 1.24 (6H, s, H-4’, H-
5’). 
13C NMR (100 MHz, CD3OD) δ 164.8 (C-2), 162.2 (C-7), 156.5 (C-9), 147.0 (C-4), 
132.5 (C-5), 127.3 (C-6), 113.8 (C-10), 113.0 (C-3), 103.9 (C-8), 80.0 (C-2’), 74.6 
(C-3’), 34.2 (C-1’), 26.4 (C-4’), 26.0 (C-5’). 
ESIMS m/z 265 [M+H]+ 
 
7.4.57. peucedanol 7-O-β-D-glucopyranoside (57)  
White amorphous powder 
C20H26O10  
[α]20D -0.3 (c 1.0, MeOH) 
UV (MeOH) λmax (log ε) 223 (3.77), 244 (3.15), 253 (3.04), 293 (3.43), 328 (3.58) 
nm 
1H NMR (400 MHz, CD3OD) δ 7.86 (1H, d, J = 9.5 Hz, H-4), 7.44 (1H, s, H-5), 7.16 
(1H, s, H-8), 6.25 (1H, d, J = 9.5 Hz, H-3), 4.96 (1H, d, J = 7.2 Hz, H-1’’), 3.93 (1H, 
dd, J = 12.1, 2.0 Hz, H-6’’a), 3.71 (1H, dd, J = 12.1, 5.7 Hz, H-6’’b), 3.46~3.56 (4H, 
m, H-3’’, H-2’, H-5’’, H-2’’), 3.35~3.43 (2H, m, H-4’’, H-1’a), 2.33 (1H, dd, J = 
13.5, 10.0 Hz, H-1’b), 1.24 (3H, s, H-4’), 1.23 (3H, s, H-5’). 
13C NMR (100 MHz, CD3OD) δ 164.2 (C-2), 160.9 (C-7), 156.3 (C-9), 146.6 (C-4), 
132.0 (C-5), 129.7 (C-6), 115.5 (C-10), 114.9 (C-3), 104.6 (C-8), 103.4 (C-1’’), 79.9 
(C-2’), 79.2 (C-5’’), 78.5 (C-3’’), 75.6 (C-2’’), 75.0 (C-3’), 72.1 (C-4’’), 63.2 (C-6’’), 
34.1 (C-1’), 28.1 (C-4’), 24.1 (C-5’). 
ESIMS m/z 427 [M+H]+ 
 
7.4.58. peujaponiside (58) 
White amorphous powder 
C25H34O14  
[α]20D +2.6 (c 0.1, MeOH) 
UV (MeOH) λmax (log ε) 223 (3.48), 254 (2.80), 294 (3.13), 328 (3.26) nm 
1H NMR (400 MHz, CD3OD) δ 7.88 (1H, d, J = 9.5 Hz, H-4), 7.45 (1H, s, H-5), 7.26 
(1H, s, H-8), 6.28 (1H, d, J = 9.5 Hz, H-3), 4.97 (1H, d, J = 2.6 Hz, H-1’’’), 4.90 (1H, 




Hz, H-4’’’b), 3.71 (1H, m, H-6’’b), 3.65 (2H, s, H-5’’a, H-5’’b), 3.45~3.64 (4H, m, 
H-2’, H-2’’, H-5’’, H-3’’), 3.32~3.40 (2H, m, H-1’a, H-4’’), 2.33 (1H, dd, J = 13.5, 
9.9 Hz, H-1’b), 1.24 (3H, s, H-4’), 1.23 (3H, s, H-5’). 
13C NMR (100 MHz, CD3OD) δ 164.5 (C-2), 160.9 (C-7), 156.3 (C-9), 146.7 (C-4), 
132.0 (C-5), 129.8 (C-6), 115.6 (C-10), 114.9 (C-3), 112.1 (C-1’’’), 105.0 (C-8), 
103.6 (C-1’’), 81.3 (C3’’’), 79.9 (C-2’), 79.2 (C-2’’’), 78.7 (C-5’’), 78.0 (C-3’’), 75.9 
(C-4’’’), 75.7 (C-2’’), 75.0 (C-3’), 72.7 (C-4’’), 70.1 (C-6’’), 66.5 (C-5’’’), 34.2 (C-
1’), 28.2 (C-4’), 24.0 (C-5’). 
ESIMS m/z 559 [M+H]+ 
 
7.4.59. eugenin (59)  
White amorphous powder 
C11H10O4  
[α]20D +29.5 (c 0.1, MeOH) 
UV (MeOH) λmax (log ε) 232 (3.24), 251 (3.29), 257 (3.29), 292 (2.91), 320 (2.67) 
nm 
1H NMR (400 MHz, CDCl3) δ 6.34 (1H, d, J = 2.2 Hz, H-8), 6.32 (1H, d, J = 2.2 Hz, 
H-6), 6.01 (1H, s, H-3), 3.83 (3H, s, 7-OMe), 2.33 (3H, s, 2-Me). 
13C NMR (100 MHz, CDCl3) δ 182.5 (C-4), 166.8 (C-2), 165.3 (C-7), 162.2 (C-5), 
158.1 (C-9), 108.8 (C-3), 105.2 (C-10), 97.9 (C-6), 92.5 (C-8), 55.7 (7-OMe), 20.5 
(2-Me). 
ESIMS m/z 207 [M+H]+ 
 
7.4.60. 6,β-dihydroxyphenethyl trans-ferulate (decursidate) (60)  
White amorphous powder 
C18H18O6  
[α]20D +43.2 (c 0.1, MeOH) 
UV (MeOH) λmax (log ε) 225 (4.26), 287 (4.06), 322 (4.14) nm 
1H NMR (500 MHz, CD3OD) δ 7.59 (1H, d, J = 15.9 Hz, H-7), 7.24 (2H, d, J = 8.5 
Hz, H-2’, H-6’), 7.09 (1H, d, J = 1.6 Hz, H-2), 7.00 (1H, dd, J = 8.5, 1.6 Hz, H-6), 
6.79 (3H, d, J = 8.5, H-5, H-3’, H-5’), 6.33 (1H, d, J = 15.9 Hz, H-8), 4.87 (1H, m, 




13C NMR (125 MHz, CD3OD) δ 169.9 (C-9), 158.9 (C-4’), 151.2 (C-4), 149.9 (C-3), 
147.8 (C-7), 133.7 (C-1’), 129.4 (C-2’, C-6’), 128.4 (C-1), 124.8 (C-6), 117.2 (C-5), 
116.9 (C-3’, C-5’), 116.0 (C-8), 112.4 (C-2), 73.4 (C-7’), 70.8 (C-8’), 57.1 (3-OMe). 
ESIMS m/z 329 [M-H]- 
 
7.4.61. 6-hydroxyphenethyl cis-ferulate (61) 
White amorphous powder 
C18H18O5 
[α]20D +19.8 (c 0.1, MeOH) 
UV (MeOH) λmax (log ε) 224 (3.89), 288 (3.61), 326 (3.74) nm 
1H NMR (800 MHz, CD3OD) δ 7.72 (1H, d, J = 1.9 Hz, H-2), 7.09 (1H, dd, J = 8.2, 
1.9 Hz, H-6), 7.05 (2H, d, J = 8.5 Hz, H-2’, H-6’), 6.86 (1H, d, J = 12.8 Hz, H-7), 
6.77 (1H, d, J = 8.2 Hz, H-5), 6.72 (2H, d, J = 8.5 Hz, H-3’, H-5’), 5.78 (1H, d, J = 
12.8 Hz, H-8), 4.29 (2H, t, J = 7.1 Hz, H-8’), 3.86 (3H, s, 3-OMe), 2.86 (2H, t, J = 
7.1 Hz, H-7’). 
13C NMR (200 MHz, CD3OD) δ 169.1 (C-9), 157.9 (C-4’), 150.3 (C-4), 149.1 (C-3), 
146.1 (C-7), 131.7 (C-2’, C-6’), 130.9 (C-1’), 128.9 (C-1), 127.4 (C-6), 117.5 (C-8), 
117.0 (C-3’, C-5’), 116.4 (C-5), 115.7 (C-2), 67.1 (C-8’), 57.1 (3-OMe), 36.1 (C-7’). 
ESIMS m/z 313 [M-H]- 
 
7.4.62. (-)-pinoresinol (62) 
White amorphous powder 
C20H22O6 
[α]20D -13.3 (c 1.0, MeOH)  
UV (MeOH) λmax (log ε) 234 (4.13), 283 (3.82), 327 (3.27) nm 
CD (MeOH) λmax (Δε) 228 (-0.74), 280 (-0.29) nm 
1H NMR (600 MHz, CD3OD) δ 6.92 (2H, d, J = 1.8 Hz, H-2, H-2’), 6.79 (2H, dd, J 
= 8.1, 1.8 Hz, H-6, H-6’), 6.74 (2H, d, J = 8.1 Hz, H-5, H-5’), 4.68 (2H, d, J = 4.4 
Hz, H-7, H-7’), 4.21 (2H, dd, J = 9.2, 7.0 Hz, H-9a, H-9’a), 3.83 (6H, s, 3-OMe, 3’-
OMe), 3.82 (2H, dd, J = 9.2, 3.7 Hz, H-9b, H-9’b), 3.12 (2H, m, H-8, H-8’). 
13C NMR (150 MHz, CD3OD) δ 147.8 (C-3, C-3’), 146.0 (C-4, C-4’), 132.5 (C-1, 




(C-9, C-9’), 55.1 (3-OMe, 3’-OMe), 54.0 (C-8, C-8’). 
ESIMS m/z 381 [M+Na]+ 
 
7.4.63. trans-ferulic acid (63)  
White amorphous powder 
C10H10O4 
[α]20D -0.2 (c 1.0, MeOH)  
UV (MeOH) λmax (log ε) 233 (3.88), 290 (3.84), 322 (3.90) nm 
1H NMR (500 MHz, CD3OD) δ 7.58 (1H, d, J = 15.8 Hz, H-7), 7.17 (1H, s, H-2), 
7.05 (1H, d, J = 8.1 Hz, H-6), 6.80 (1H, d, J = 8.1 Hz, H-5), 6.30 (1H, d, J = 15.8 
Hz, H-8), 3.88 (3H, s, 3-OMe). 
13C NMR (125 MHz, CD3OD) δ 171.9 (C-9), 151.3 (C-4), 150.2 (C-3), 147.6 (C-7), 
128.6 (C-1), 124.8 (C-6), 117.3 (C-5), 116.9 (C-8), 112.5 (C-2), 57.2 (3-OMe). 
ESIMS m/z 195 [M+H]+ 
 
7.4.64. 3-formylindole (64)  
White amorphous powder 
C9H7NO 
[α]20D +3.6 (c 1.0, MeOH) 
UV (MeOH) λmax (log ε) 245 (3.83), 263 (3.75), 298 (3.80) nm 
1H NMR (600 MHz, CD3OD) δ 9.86 (1H, s, 3-CHO), 8.13 (1H, d, J = 7.9 Hz, H-4), 
8.07 (1H, s, H-2), 7.45 (1H, d, J = 7.9 Hz, H-7), 7.25 (1H, t, J = 7.9 Hz, H-6), 7.21 
(1H, t, J = 7.9 Hz, H-5). 
13C NMR (150 MHz, CD3OD) δ 186.1 (3-CHO), 138.3 (C-2), 137.6 (C-8), 124.4 (C-
9), 123.7 (C-6), 122.3 (C-5), 121.0 (C-4), 118.8 (C-3), 111.8 (C-7). 









Table 3. 1H-NMR Data of Compounds 1-8 (δ in ppm; J in Hz) 
position 1a 2a 3a 4a 5c 6a 7b 8d 
3 6.20, d (9.5) 6.19, d (9.5) 6.20, d (9.5) 6.19, d (9.5) 6.20, d (9.5) 6.20, d (9.5) 6.20, d (9.5) 6.20, d (9.5) 
4 7.57, d (9.5) 7.56, d (9,5) 7.57, d (9.5) 7.56, d (9,5) 7.57, d (9.5) 7.57, d (9.5) 7.57, d (9.5) 7.57, d (9.5) 
5 7.33, d (8.6) 7.32, d (8.6) 7.33, d (8.6) 7.32, d (8.6) 7.33, d (8.6) 7.33, d (8.6) 7.34, d (8.6) 7.33, d (8.6) 
6 6.78, d (8.6) 6.77, d (8.6) 6.78, d (8.6) 6.77, d (8.6) 6.79, d (8.6) 6.77, d (8.6) 6.78, d (8.6) 6.78, d (8.6) 
3’ 5.30, d (4.8) 5.29, d (4.8) 5.31, d (4.9) 5.31, d (4.9) 5.35, d (5.0) 5.29, d (4.9) 5.36, d (4.9) 5.31, d (4.9) 
4’ 6.53, d (4.8) 6.56, d (4.8) 6.54, d (4.9) 6.59, d (4.9) 6.56, d (5.0) 6.55, d (4.9) 6.63, d (4.9) 6.52, d (4.9) 
5’ 1.38, s 1.40, s 1.38, s 1.39, s 1.40, s 1.38, s 1.41, s 1.39, s 
6’ 1.43, s 1.44, s 1.43, s 1.44, s 1.44, s 1.43, s 1.45, s 1.43, s 
3’-ester         
2 2.55, sep 
(7.0) 










3 1.18, d (7.0)  1.69, m 1.68, m  1.17, d (7.0) 1.68, m 1.66, sxt 
(7.4) 
   1.46, m 1.45, m   1.46, m  
4 1.17, d (7.0)  0.90, t (7.4) 0.89, t (7.4) 2.17, brs 1.16, d (7.0) 0.89, t (7.5) 0.95, t (7.4) 
5   1.14, d (7.0) 1.14, d (7.0) 1.89, brs  1.13, d (7.0)  
4’-ester         
2 2.37, sxt 
(7.0) 
5.62, s 2.56, sep 
(7.0) 




 2.38, sxt 
(7.0) 
      2.17, m   
3 1.71, m  1.20, d (7.0)  1.71, m 2.13, m 6.00, q (7.2) 1.71, m 
 1.44, m    1.43, m   1.45, m 
4 0.91, t (7.4) 2.21, s 1.17, d (7.0) 2.21, s 0.91, t (7.4) 0.97, d (6.3) 1.97, d (7.2) 0.92, t (7.4) 
5 1.19, d (7.0) 1.87, s  1.87, s 1.20, d (7.0) 0.95, d (6.3) 1.84, s  1.19, d (7.0) 
a Data were obtained at 400 MHz in CDCl3. 
b Data were obtained at 500 MHz in CDCl3. 
c Data were obtained at 600 MHz in CDCl3. 


















Table 4. 1H-NMR Data of Compounds 9-16 (δ in ppm; J in Hz) 
position 9d 10a 11c 12a 13d 14a 15d 16a 
3 6.20, d (9.5) 6.22, d (9.5) 6.24, d (9.5) 6.15, d (9.5) 6.24, d (9.5) 6.17, d (9.5) 6.24, d (9.5) 6.21, d (9.4) 
4 7.57, d (9.5) 7.58, d (9.5) 7.62, d (9.5) 7.56, d (9.5) 7.62, d (9.5) 7.56, d (9.5) 7.59, d (9,5) 7.58, d (9.4) 
5 7.33, d (8.6) 7.35, d (8.7) 7.37, d (8.6) 7.33, d (8.6) 7.32, d (8.6) 7.31, d (8.6) 7.29, d (8.6) 7.32, d (8.6) 
6 6.78, d (8.6) 6.79, d (8.7) 6.81, d (8.6) 6.75, d (8.6) 6.77, d (8.6) 6.75, d (8.6) 6.73, d (8.6) 6.79, d (8.6) 
3’ 5.36, d (4.9) 5.30, d (4.8) 5.41, d (4.9) 5.22, d (4.9) 5.11, d (4.9) 4.01, d (4.7) 5.16,d (4.6) 3.93, br s 
4’ 6.61, d (4.9) 6.57, d (4.8) 6.47, d (4.9) 6.44, d (4.9) 5.40, d (4.9) 6.36, d (4.7) 4.83, d (4.6) 6.08, d (3.4) 
5’ 1.41, s 1.40, s 1.40, s 1.36, s 1.39, s 1.45, s 1.37, s 1.46, s 
6’ 1.44, s 1.43, s 1.41, s 1.39, s 1.47, s 1.38, s 1.47, s 1.37, s 
3’-ester         
2 2.21, d (7.4) 
2.20, d (6.9) 
2.09, s 2.08, s 2.04, s 2.50, sxt 
(7.0) 
 2.51, sxt 
(7.0) 
5.68, s 
3 2.08, m    1.74, m  1.76, m  
     1.51, m  1.54, m  
4 0.94, d (6.6)    0.93, t (7.5)  0.95, t (7.4) 2.21, s 
5 0.93, d (6.6)    1.19, d (7.0)  1.21, d (7.0) 1.89, s 
4’-ester         
1       3.70, s  






 2.45, sxt 
(7.0) 
  
  2.50, d 
(15.4) 
      
3 6.01, q (7.3)  3.92, m 1.66, m  1.71, m   
    1.41, m  1.47, m   
4 1.98, d (7.3) 1.34, s 1.22, d (6.3) 0.88, t (7.4)  0.91, t (7.4)   
5 1.84, s  1.33, s 1.16, d (7.2) 1.15, d (7.0)  1.21, d (7.0)   
OH   3.52, d (5.4)  3.12, br s 2.96, br s   
solvent*       3.47, s  
a Data were obtained at 400 MHz in CDCl3. 
b Data were obtained at 500 MHz in CDCl3. 
c Data were obtained at 600 MHz in CDCl3. 
d Data were obtained at 800 MHz in CDCl3. 
















Table 5. 1H-NMR Data of Compounds 17-24 (δ in ppm; J in Hz) 
position 17c 18d 19c 20d 21c 22b 23c 24e 
3 6.20, d (9.5) 6.20, d (9.4) 6.23, d (9.5) 6.23, d (9.5) 6.20, d (9.5) 6.15, d (9.5) 6.20, d (9.5) 6.24, d (9.6) 
4 7.58, d (9.5) 7.57, d (9.4) 7.62, d (9.5) 7.61, d (9.5) 7.57, d (9.5) 7.55, d (9.5) 7.57, d (9.5) 7.63, d (9.6) 
5 7.32, d (8.6) 7.32, d (8.6) 7.32, d (8.6) 7.31, d (8.6) 7.33, d (8.6) 7.31, d (8.6) 7.33, d (8.6) 7.32, d (8.6) 
6 6.77, d (8.6) 6.77, d (8.6) 6.78, d (8.6) 6.77, d (8.6) 6.66, d (8.6) 6.75, d (8.6) 6.78, d (8.6) 6.78, d (8.6) 
3’ 4.02, d (4.6) 4.02, dd (4.7, 
2.3) 
5.19, d (4.7) 5.20, d (4.9) 5.39, d (5.0) 5.31, d (4.8) 5.34, d (4.9) 5.18, d (5.0) 
4’ 6.43, d (4.6) 6.43, d (4.7) 5.42, d (4.7) 5.42, d (4.9) 6.66, d (5.0) 6.57, d (4.8) 6.58, d (4.9) 5.40, d (5.0) 
5’ 1.45, s 1.45, s 1.39, s 1.39, s 1.43, s 1.38, s 1.40, s 1.38, s 
6’ 1.43, s 1.42, s 1.48, s 1.47, s 1.45, s 1.42, s 1.44, s 1.46, s 
3’-ester         
2   5.79, s 5.78, brs 5.64, br s 5.62, s 5.66, br s 2.16, s 
3         
4   2.19, s 2.19, brs 2.14, br s 2.11, s 2.16, br s  
5   1.91, s 1.91, brs 1.83, br s 1.84, s 1.88, br s  
4’-ester         
2 5.71, s 5.71, brs    5.58, s 2.29, dd 
(14.9, 6.9) 
 
       2.20, m  
3     5.98, qd (7.2, 
1.4) 
 2.12, m  
4 2.22, s 2.23, brs   1.97, dd (7.2, 
1.4) 
2.14, s 0.97, d (6.6)  
5 1.90, s 1.90, brs   1.83, br s  1.83, s 0.95, d (6.6)  
OH 2.98, br s 2.92, d (2.3) 3.16, br s 3.02, br s     
solvent*  3.47, s       
a Data were obtained at 400 MHz in CDCl3. 
b Data were obtained at 500 MHz in CDCl3. 
c Data were obtained at 600 MHz in CDCl3. 
d Data were obtained at 800 MHz in CDCl3. 
e Data were obtained at 300 MHz in CDCl3. 

















Table 6. 1H-NMR Data of Compounds 25-32 (δ in ppm; J in Hz) 
position 25a 26a 27c 28e 29f 30d 31c 32a 
3 6.13, d (9.5) 6.21, d (9.5) 6.22, d (9.4) 6.24, d (9.5) 6.22, d (9.4) 6.20, d (9.5) 6.19, d (9.5) 6.17, d (9.5) 
4 7.56, d (9.5) 7.57, d (9.5) 7.58, d (9.4) 7.86, d (9.5) 7.59, d (9.4) 7.58, d (9.5) 7.57, d (9,5) 7.57, d (9.5) 
5 7.32, d (8.6) 7.33, d (8.6) 7.34, d (8.6) 7.45, d (8.6) 7.33, d (8.6) 7.34, d (8.6) 7.23, d (8.6) 7.33, d (8.7) 
6 6.74, d (8.6) 6.78, d (8.6) 6.78, d (8.6) 6.77, d (8.6) 6.78, d (8.6) 6.78, d (8.6) 6.78, d (8.6) 6.78, d (8.7) 
3’ 5.24, d (4.9) 5.30, d (4.9) 5.30, d (4.9) 3.75, d (4.7) 3.98, d (4.6) 4.06, d (4.7) 5.37, d (4.8) 5.40, d (4.9) 
4’ 6.53, d (4.9) 6.51, d (4.9) 6.54, d (4.9) 5.09, d (4.7) 6.40, d (4.6) 6.47, d (4.7) 6.58, d (4.8) 6.66, d (4.9) 
5’ 1.35, s 1.40, s 1.41, s 1.422, s 1.43, s 1.47, s 1.42, s 1.42, s 
6’ 1.38, s 1.43, s 1.44, s 1.418, s 1.42, s 1.42, s 1.45, s 1.45, s 
3’-ester         
2 2.01, s 2.07, s 2.09, s      
3       6.09, q (7.2) 6.08, q (7.2) 
4       1.94, d (7.2) 1.94, d (7.2) 
5       1.85, s  1.82, s  
4’-ester         




 2.21, s  2.35, sxt 
(7.0) 
 
   2.21, dd 
(14.8, 7.1) 
     
3 5.94, q (7.2) 1.21, d (7.0) 2.14, m   6.09, q (7.3) 1.69, m 5.99, q (7.2) 
       1.40, m  
4 1.90, d (7.2) 1.18, d (7.0) 0.99, d (6.7)   1.99, d (7.3) 0.87, t (7.5) 1.92, d (7.2) 
5 1.78, s   0.97, d (6.7)   1.87, br s  1.16, d (7.0) 1.79, s  
OH      2.83, s   
solvent* 3.37, s       3.44, s 
a Data were obtained at 400 MHz in CDCl3. 
b Data were obtained at 500 MHz in CDCl3. 
c Data were obtained at 600 MHz in CDCl3. 
d Data were obtained at 800 MHz in CDCl3. 
e Data were obtained at 100 MHz in CD3OD. 
f Data were obtained at 300 MHz in CDCl3. 

















Table 7. 1H-NMR Data of Compounds 33-40 (δ in ppm; J in Hz) 
position 33a 34a 35c 36e 37c 38e 39d 40f 
3 6.22, d (9.5) 6.18, d (9.5) 6.19, d (9.6) 6.19, d (9.5) 6.16, d (9.5) 6.21, d (9.4) 6.22, d (9.4) 6.24, d (9.5) 
4 7.61, d (9.5) 7.55, d (9.5) 7.55, d (9.6) 7.57, d (9.5) 7.57, d (9.5) 7.60, d (9.4) 7.61, d (9,4) 7.86, d (9.5) 
5 7.31, d (8.6) 7.32, d (8.6) 7.32, d (8.7) 7.33, d (8.7) 7.33, d (8.6) 7.23, d (8.6) 7.24, d (8.6) 7.53, d (8.7) 
6 6.77, d (8.6) 6.77, d (8.6) 6.77, d (8.7) 6.76, d (8.7) 6.76, d (8.6) 6.77, d (8.6) 6.73, d (8.6) 6.84, d (8.7) 
3’ 5.20, d (4.8) 5.38, d (4.8) 5.31, d (4.6) 5.29, d (5.0) 5.26, d (5.1) 5.13, t (4.9) 5.12, t (5.2) 5.28, d (4.8) 




6.49, d (4.8) 





5’ 1.41, s 1.42, s 1.39, s 1.38, s 1.37, s 1.36, s 1.35, s 1.42, s 
6’ 1.49, s 1.47, s 1.43, s 1.41, s 1.40, s 1.33, s 1.33, s 1.44, s 
3’-ester         
2   2.20, m 2.26, m 2.19, m 5.63, br s 2.18, d (7.2) 2.07, s 
   2.20, m 2.19, m 2.19, m  2.18, d (7.2)  
3 6.14, q (7.2) 6.08, q (7.3) 2.08, m 2.11, m 2.07, m  2.06, m  
4 1.97, d (7.2) 1.94, d (7.3) 0.94, d (7.1) 0.94, d (6.4) 0.94, d (6.4) 2.13, br s 0.91, d (6.7)  
5 1.91, br s  1.83, s  0.93, d (7.1) 0.94, d (6.4) 0.92, d (6.4) 1.85, br s 0.91, d (6.7)  
4’-ester         
2  5.59, s 5.61, s 2.26, m 2.34, sxt 
(7.0) 
  2.09, s 
    2.19, m     
3    2.11, m 1.68, m    
     1.47, m    
4  2.16, s 2.21, s 0.94, d (6.4) 0.90, t (7.4)    
5  1.85, s 1.87, s 0.94, d (6.4) 1.16, d (7.0)    
a Data were obtained at 400 MHz in CDCl3. 
b Data were obtained at 500 MHz in CDCl3. 
c Data were obtained at 600 MHz in CDCl3. 
d Data were obtained at 800 MHz in CDCl3. 
e Data were obtained at 300 MHz in CDCl3. 
f Data were obtained at 500 MHz in CD3OD. 
















Table 8. 1H-NMR data of compounds 41-43 (δ in ppm; J in Hz).  
position 41b 42a 43b 
3 6.21, d (9.6) 6.21, d (9.5) 6.21, d (9.6) 
4 7.59, d (9.6) 7.59, d (9.6) 7.60, d (9.6) 
5 7.38, d (8.4) 7.39, d (8.4) 7.39, d (8.4) 
6 6.77, d (8.4) 6.78, d (8.2) 6.77, d (8.4) 
3’ 6.74, s 6.75, s 6.74, s 
5’ 1.36, s 1.39, s 1.38, s 
6’ 1.36, s 1.34, s 1.33, s 
3’-ester    
2 5.73, s 2.50, sxt (6.9) 2.33, d (7.3) 
   2.30, d (7.1) 
3  1.76, m 2.16, m 
  1.53, m  
4 2.22, s 0.95, t (7.3) 0.98, d (6.7) 
5 1.91, s 1.20, d (6.9) 0.98, d (6.7) 
2’-OH 4.20, br s 4.14, br s 4.20, br s 
a Data were obtained at 400 MHz in CDCl3. 























Table 9. 13C-NMR Data of Compounds 1-10 (δ in ppm) 
position 1a 2a 3a 4a 5c 6a 7b 8d 9d 10a 
2 159.7 159.8 159.7 159.9 159.8 159.7 159.8 159.7 159.7 159.9 
3 113.3 113.3 113.2 113.3 113.3 113.2 113.3 113.3 113.3 113.2 
4 143.1 143.1 143.2 143.1 143.3 143.2 143.2 143.1 143.2 143.3 
5 129.2 129.1 129.1 129.0 129.2 129.2 129.2 129.2 129.2 129.4 
6 114.4 114.4 114.4 114.3 114.5 114.4 114.4 114.4 114.4 114.5 
7 156.6 156.7 156.6 156.7 156.9 156.6 156.6 156.6 156.7 156.6 
8 107.5 107.5 107.4 107.6 107.6 107.3 107.5 107.5 107.4 106.6 
9 154.0 154.0 154.0 154.0 154.2 154.0 154.0 154.0 154.1 153.9 
10 112.4 112.5 112.5 112.5 112.6 112.5 112.5 112.5 112.5 112.6 
2’ 77.4 77.4 77.5 77.5 77.8 77.5 77.4 77.3 77.4  77.2  
3’ 70.3 70.6 70.0 70.2 69.3 70.1 70.2 70.4 70.1 70.4 
4’ 60.4 59.6 60.5 59.5 60.7 60.4 60.1 60.3 60.2 61.0 
5’ 25.5 25.3 25.2 25.4 25.1 25.2 25.5 25.5 25.4 25.2 
6’ 22.0 22.3 22.3 22.3 22.5 22.3 22.2 22.0 22.3 22.2 
3’-ester           
1 175.7 169.9 175.4 175.5 165.1 175.8 175.4 172.4 171.8 169.9 
2 33.9 20.7 40.9 41.0 115.1 33.9 40.9 35.9 43.1 20.7 
3 19.1  26.6 26.6 159.0 19.1 26.6 18.2 25.3  
4 18.5  11.6 11.6 20.5 18.6 11.6 13.7 22.4  
5   16.2 16.3 27.6  16.1  22.5  
4’-ester           
1 175.4 165.2 175.7 165.0 175.4 171.9 166.7 175.5 166.7 171.8 
2 41.3 115.0 34.0 115.0 41.3 43.2 127.5 41.3 127.5 46.5 
3 26.5 158.2 18.8 158.2 26.6 25.4 138.0 26.6 137.9 69.2 
4 11.6 20.4 18.8 20.3 11.6 22.5 15.6 11.6 15.6  29.3 
5 16.4 27.5  27.5 16.6 22.5 20.4 16.5 20.4  29.2 
a Data were obtained at 100 MHz in CDCl3. 
b Data were obtained at 125 MHz in CDCl3. 
c Data were obtained at 150 MHz in CDCl3. 














Table 10. 13C-NMR Data of Compounds 11-20 (δ in ppm) 
position 11c 12a 13d 14a 15d 16a 17c 18d 19c 20d 
2 160.6 159.6 160.6 159.8 160.7 160.1 160.2 160.1 160.6 160.4 
3 112.9 113.1 112.6 112.9 112.9 113.1 113.1 113.0 112.7 112.6 
4 143.7 143.2 144.0 143.2 143.6 143.3 143.4 143.3 144.0 143.9 
5 129.4 129.3 128.8 129.3 128.9 129.1 129.3 129.2 128.8 128.7 
6 114.8 114.4 114.7 114.5 114.5 114.5 114.6 114.5 114.7 114.6 
7 156.9 156.4 156.0 156.9 156.0 157.0 157.1 157.0 156.2 156.1 
8 106.8 107.2 110.8 107.1 110.1 107.6 107.3 107.2 110.8 110.6 
9 154.0 153.8 154.3 154.1 154.3 154.2 154.3 154.2 154.5 154.4 
10 112.6 112.4 112.4 112.2 112.5 112.6 112.4 112.3 112.5 112.4 
2’ 77.5  77.0 77.5 78.5 77.7 79.3 78.8 78.7 77.9 77.8  
3’ 69.8 70.6 72.2 71.7 72.5 73.7 71.7 71.7 71.5 71.3 
4’ 61.6 60.1 59.9 63.5 69.4 67.8 63.0 63.0 60.3 60.3 
5’ 24.7 25.5 25.8 25.8 26.2 24.9 25.6 25.5 25.6 25.5 
6’ 22.6 21.6 22.3 20.6 22.2 21.0 21.3 21.2 22.7 22.6 
3’-ester           
1 170.0 169.6 176.0  176.0    165.6 165.6 
2 20.7 20.6 41.2  41.2    115.2 115.1 
3   26.7  26.8    159.3 159.3 
4   11.7  11.7    20.5 20.5  
5   16.7  16.5    27.6 27.6 
4’-ester           
1 174.3 175.5  178.2 61.0 167.3 167.6 167.5   
2 48.4 41.2  41.4  115.0 115.0 114.9   
3 69.1 26.5  26.7  159.6 159.8 159.8   
4 21.0 11.5  11.6  20.6 20.7 20.6   
5 13.9 16.4  16.5  27.6 27.7 27.7   
solvent*     50.9   50.9   
a Data were obtained at 100 MHz in CDCl3. 
b Data were obtained at 125 MHz in CDCl3. 
c Data were obtained at 150 MHz in CDCl3. 
d Data were obtained at 200 MHz in CDCl3. 













Table 11. 13C-NMR Data of Compounds 21-22 and 24-30 (δ in ppm) 
position 21c 22b 24d 25a 26a 27c 28e 29d 30d 
2 159.8 159.8 160.7 159.7 159.7 159.7 164.2 160.1 159.9 
3 113.3 113.0 112.2 112.9 113.3 113.3 113.5 113.0 113.0 
4 143.2 143.2 144.2 143.3 143.2 143.1 147.0 143.4 143.3 
5 129.1 129.0 128.6 129.3 129.2 129.2 130.9 129.2 129.3 
6 114.5 114.3 114.9 114.3 114.4 114.4 116.6 114.5 114.5 
7 156.9 156.7 156.4 156.4 156.6 156.6 158.7 156.9 156.9 
8 107.6 107.5 106.7 107.0 107.2 107.2 113.6 106.7 107.1 
9 154.2 154.0 154.6 153.8 154.1 154.0 156.5 154.2 154.2 
10 112.6 112.4 110.6 112.4 112.5 112.5 114.5 112.4 112.3 
2’ 77.7 77.6 79.0 77.0 77.2 77.4 81.0 78.7 78.6  
3’ 69.4 69.3 70.8 70.5 70.3 70.5 73.9 71.0 71.7 
4’ 60.5 59.7 61.4 59.9 60.5 60.4 62.9 63.9 63.5 
5’ 25.2 25.0 24.8 25.2 25.1 25.3 27.6 25.0 25.6 
6’ 22.6 22.5 21.9 21.8 22.3 22.2 22.3 21.7 20.9 
3’-ester          
1 165.2 165.1 172.0 169.7 169.8 169.8    
2 115.3 115.24 20.9 20.5 20.7 20.7    
3 158.7 158.1        
4 22.6 20.3        
5 27.6 27.4        
4’-ester          
1 166.8 165.0  166.8 175.8 171.9  172.1 169.2 
2 127.8 115.17  127.3 34.1 43.3  20.9 127.3 
3 137.6 157.4  137.5 18.9 25.5   139.1 
4 15.6  20.2  15.3  18.8 22.44   15.8 
5 20.5  27.3  20.2   22.40   20.4  
solvent*    50.3    50.9  
a Data were obtained at 100 MHz in CDCl3. 
b Data were obtained at 125 MHz in CDCl3. 
c Data were obtained at 150 MHz in CDCl3. 
d Data were obtained at 200 MHz in CDCl3. 
e Data were obtained at 100 MHz in CD3OD. 













Table 12. 13C-NMR Data of Compounds 31-40 (δ in ppm) 
position 31c 32e 33a 34a 35c 36e 37c 38e 39d 40f 
2 159.7 159.8 160.5 159.8 159.9 159.7 159.6 161.2 161.2 162.8 
3 113.2 113.1 112.6 113.3 113.4 113.2 113.1 112.5 112.6 114.3 
4 143.2 143.2 143.9 143.1 143.2 143.2 143.1 143.8 143.8 146.5 
5 129.2 129.2 128.7 129.0 129.1 129.2 129.3 126.6 126.7 131.8 
6 114.3 114.3 114.6 114.3 114.4 114.3 114.3 114.3 114.3 116.5 
7 156.6 156.6 156.0 156.7 156.8 156.6 156.4 156.3 156.2 158.8 
8 107.5 107.4 110.8 107.7 107.7 107.2 107.3 107.2 107.0 108.8 
9 154.0 153.9 154.4 154.1 154.1 153.9 153.8 153.4 153.4 155.9 
10 112.4 112.4 112.4 112.5 112.6 112.4 112.3 112.1 112.1 114.9 
2’ 77.5 77.3 77.6 77.5 77.6 77.4 77.2 77.2 76.5  79.4 
3’ 70.2 70.1 72.4 70.3 70.3 70.2 70.3 68.3 69.2 72.6 
4’ 60.5 60.1 60.0 59.5 59.7 60.4 60.2 23.1 23.1 63.1 
5’ 25.3 25.4 25.7 25.5 25.4 25.31 25.6 23.0 22.7 26.2 
6’ 22.5 22.4 22.6 22.5 22.6 22.4 21.8 24.6 24.7 23.3 
3’-ester           
1 166.3 166.4 166.9 166.3 172.0 171.81 171.6 165.5 172.2 172.7 
2 127.0 127.2 127.2 127.2 43.2 43.2 43.0 115.5 43.4 21.4 
3 139.6 139.8 139.5 139.3 25.4 25.4 25.3 158.3 25.7  
4 15.7  15.7  15.8  15.7  22.5 22.4 22.4 20.3 22.4  
5 20.4  20.4  20.6  20.3  22.5 22.4 22.3 27.5 22.3  
4’-ester           
1 175.2 166.2  165.0 165.2 171.78 175.3   172.4 
2 41.2 126.8  115.1 115.2 43.0 41.2   21.3 
3 26.4 138.4  157.8 158.2 25.34 26.5    
4 11.5 15.5   20.4 20.5 22.4 11.6    
5 16.2 20.3   27.4 27.5 22.3 16.5    
solvent*  50.7         
a Data were obtained at 100 MHz in CDCl3. 
b Data were obtained at 125 MHz in CDCl3. 
c Data were obtained at 150 MHz in CDCl3. 
d Data were obtained at 200 MHz in CDCl3. 
e Data were obtained at 75 MHz in CDCl3. 
f Data were obtained at 125 MHz in CD3OD. 













Table 13. 13C-NMR data of compounds 41-43 (δ in ppm).  
position 41b 42a 43b 
2 159.9 159.6 159.7 
3 113.2 113.3 113.3 
4 143.5 143.4 143.4 
5 131.4 131.5 131.5 
6 107.1 107.1 107.1 
7 162.0 161.8 161.9 
8 111.3 111.1 111.1 
9 151.8 151.9 151.8 
10 113.4 113.4 113.4 
2’ 112.8 112.8 112.7 
3’ 67.9 68.5 68.5 
4’ 74.5 74.6 74.6 
5’ 23.8 23.8 23.7 
6’ 23.7 23.7 23.7 
3’-ester    
1 164.4 175.0 171.3 
2 114.2 41.3 43.1 
3 161.1 26.8 25.8 
4 20.7 11.5 22.4 
5 27.6 16.6 22.3 
a Data were obtained at 100 MHz in CDCl3. 


















7.5. Partial and total alkaline hydrolysis of 1 
 
Compound 1 (3.2 mg) was dissolved in 1,4-dioxane (0.5 ml) and 0.5 M KOH (0.5 
ml) was added at room temperature. The NP-TLC was performed with n-hexane and 
EtOAc (2:1) to confirm reaction progress. After 2 min, the reaction mixture was 
neutralized with 5% H2SO4 (~120 μl), extracted with CHCl3 (1 ml), and concentrated. 
Hydrolysis product, 1a (tR = 11.0 min), 1b (tR = 7.1 min), and 1c (tR = 7.6 min), were 



























Scheme 6. Reaction of partial and total alkaline hydrolysis of 1 
 
7.6. Preparation of MTPA esters of 1a 
 
Compound 1a was dissolved in deuterated pyridine (800 μl) and (R)-(-)-MTPA-
Cl (10 μl, 0.05 mmol) and DMAP were added. The mixture was left at room 
temperature overnight, evaporated, and dissolved in CHCl3 (50 μl). Reaction process 
was confirmed by silica TLC using n-hexane and EtOAc (2:1). The resulting (S)-
MTPA ester 1aa (13.9 min) was purified by HPLC (CH3CN-H2O, 90:10, 2 ml/min) 
using INNO C18 column (10 × 250 mm, S-5 μm, 12 nm). Likewise, (S)-(+)-MTPA-









7.7. Preparation of MTPA esters of 16 
 
Compound 16 (0.4 mg, 0.001 mmol) was resuspended in deuterated pyridine (600 
μl), and reacted with (R)-(-)-MTPA-Cl (10 μl, 0.05 mmol) under nitrogen gas stream. 
The resulting mixture was subjected to silica capillary CC (7 x 0.5 cm) eluting with 
n-hexane-EtOAc (5:1). Fifty drops were collected in a vial and (S)-MTPA ester was 
attained from 15th-21st vial. The analytical NP-TLC (n-hexane-EtOAc, 3:1) was 
applied to confirm reaction progress. In the same manner, (S)-(+)-MTPA-Cl (10 μl, 
























7.8. Preparation of MTPA esters of 17 and 18 
 
Enantiomeric mixture E1 (mixture of 17 and 18, 0.5 mg) was substituted with 
nitrogen gas, deuterated pyridine (800 μl), (R)-(-)-MTPA-Cl (10 μl, 0.05 mmol), and 
DMAP were added. The progress of reaction was confirmed by silica TLC using n-
hexane and EtOAc (2:1). The resulting (S)-MTPA esters 17a (53.8 min) and 18a 
(49.7 min) were isolated by HPLC (CH3CN-H2O, 75:25. 5 ml/min) with INNO C18 
column (20 × 250 mm, S-5 μm, 12 nm). To obtain (R)-MTPA esters 17b (49.4 min) 
and 18b (53.5 min), (S)-(+)-MTPA-Cl (10 μl, 0.05 mmol) was reacted with E1 (0.4 
mg). Resulting MTPA esters were confirmed by NMR and ECD spectra (Figure 95). 
 
Figure 95. ECD curves of MTPA esters of E1 (mixture of enantiomers 17 and 18) 
 
7.9. Preparation of MTPA esters of 19 and 20 
 
In the same manner with 17 and 18, (S)-MTPA esters 19a (66.1 min) and 20a (70.4 
min), (R)-MTPA esters 20b (66.2 min) and 19b (70.5 min) were yielded. Obtained 





























7.10. X-ray crystallographic analysis of 1 and 2 
 
Diffraction data were collected by SuperNova, Dual, Cu at zero, AtlasS2 
diffractometer with Cu Kα radiation (λ = 1.54184). Using Olex2, the structure was 
solved by direct methods with ShelXT structure solution program and refined by 
Least Squares minimization with ShelXL refinement package. The crystallographic 
data of 1 and 2 were deposited at the Cambridge Crystallographic Data Centre 
(CCDC deposition number, 1: 1488681, 2: 1474283).  
 
7.10.1. Crystal data of 1  
 
colorless crystal, C23H28O7, M = 416.45, monoclinic, crystal size 0.3 × 0.101 × 
0.031 mm3, space group P21 (no. 4), a = 24.3633(4) Å , b = 9.12727(13) Å , c = 
31.0898(6) Å , β = 109.128(2)°, V = 6531.8(2) Å 3, Z = 12, T = 100(80) K, μ (Cu Kα) 
= 0.774 mm-1, Dcalc = 1.270 g/cm3, 39478 reflections collected (7.274° ≤ 2Θ ≤ 
153.672°), 20639 independent reflections (Rint = 0.0243, Rsigma = 0.0335), Goodness 
of fit on F2 = 1.031, final R1 0.0417 (I> 2σ (I)), 0.0464 (all data), final wR2 0.1069 
(I> 2σ (I)), 0.1107 (all data), Flack parameter = 0.08(6). 
 
7.10.2. Crystal data of 2 
 
colorless crystal, C21H22O7, M = 386.38, monoclinic, crystal size 0.2 × 0.059 × 
0.024 mm3, space group P21 (no. 4), a = 9.68785(12) Å , b = 6.62844(9) Å , c = 
15.2024(2) Å , β = 103.8888(13)°, V = 947.69(2) Å 3, Z = 2, T = 100.0(2) K, μ (Cu 
Kα) = 0.851 mm-1, Dcalc = 1.354 g/cm3, 19091 reflections collected (9.404° ≤ 2Θ ≤ 
152.988°), 3883 independent reflections (Rint = 0.0347, Rsigma = 0.0220), Goodness 
of fit on F2 = 1.062, final R1 0.0276 (I> 2σ (I)), 0.0287 (all data), final wR2 0.0705 







7.11. ECD calculation 
 
The ground-state geometry optimization was performed in Turbomole using def-
SV(P) basis set, B3LYP functional, and density functional theory (DFT) method. 
The calculated ECD data were acquired by TD-DFT using the basis set def-SV(P) 
and B3LYP functional. Using Gaussian functions, the ECD spectra were simulated 
by overlapping each transition. (σ: width of the band at 1/e height, ΔEi : excitation 
energies for transition i, Ri : rotatory strengths for transition i, σ was 0.10 eV in this 
work) 
 
∆ϵ(𝐸) =  
1




























7.12. Evaluation of inhibitory effect on NO production in




Dulbecco’s modified Eagle’s media (DMEM), fetal bovine serum (FBS), and 
phosphate buffered saline (PBS) were purchased from Hyclone Laboratories, Inc. 
(Logan, UT, USA). Penicillin (10,000 units/ml)/streptomycin (10 mg/ml) and 0.25% 
trypsin-EDTA were obtained from Life Technologies Corporation (Grand Island, NY, 
USA). Lipopolysaccharides (LPS, from Escherichia coli 0111:B4), Nω-Nitro-L-
arginine methyl ester hydrochloride (L-NAME), sodium nitrite, sulfanilamide, N-(1-
Naphthyl)ethylenediamine dihydrochloride (NEDHC), thiazolyl blue tetrazolium 
bromide (MTT), and dimethyl sulfoxide (DMSO, 99.9%) were purchased from 
Sigma-Aldrich Co. (St. Louis, MO, USA). Phosphoric acid (85.0%) and DMSO 
(99.5%) were obtained from Daejung Chemicals & Metals Co., Ltd. (Siheung, 
Korea). Multi well culture plate (48 well and 96 well) was purchased from SPL Life 
Sciences Co., Ltd. (Pocheon, Korea) and cell culture dish (100π) from Thermo Fisher 
Scientific Inc. (Waltham, MA, USA). 
 
7.12.2. Cell cultures 
 
  RAW264.7 cells were acquired from Korean Cell Line Bank (Seoul, Korea) and 
maintained in DMEM with 10% FBS and 1% penicillin/streptomycin.  
 
7.12.3. Griess assay 
 
  RAW264.7 cells were seeded at 1 x 106 cells/ml in 48 well plates and incubated 
for 24 h and treated with compounds for 1 h before adding LPS (1 ng/ml). The final 
DMSO concentration was maintained under 0.05%. After 16 h incubation, 100 μl of 
sample aliquots were transferred to a 96 well plate and mixed with 100 μl of mixture 




phosphoric acid). The absorbance was measured at 550 nm. The NO concentration 
was calculated using nitrite standard curve (Dawson et al. 1994). 
 
7.12.4. MTT assay 
 
  After moving 100μl of sample aliquots for Griess assay, MTT solution (2 mg/ml, 
20 μl) was added to each well in 48 well plate, which were incubated for 1 h 30 min. 
The supernatant was removed and formazan was dissolved with 200 μl of DMSO 
and 100 μl of solution was transferred to a 96 well plate. The absorbance was 
measured at 540 nm. The percent cell viability is absorbance of sample-treated well 





















Chapter 8. Conclusion 
 
Sixteen new khellactone esters (1-16) and three new angular furanocoumarins (41-
43) were isolated from the n-hexane and CHCl3 fractions of the Peucedanum 
japonicum roots. Additionally, forty-five known compounds were obtained, which 
were identified as angular dihydropyranocoumarins (17-40), linear furanocoumarins 
(44-47), an angular dihydrofuranocoumarin (48), a linear dihydropyranocoumarin 
(49), simple coumarins (50-58), a chromone (59), ferulic acid derivatives (60-61), a 
lignan (62), a phenylpropanoid (63), and an indole alkaloid (64). 
An angular dihydropyranocoumarin moiety was easily identified by typical 
chemical shift and coupling constant in 1H NMR. The position of the substituents at 
3’ and 4’ was determined by HMBC and partly with MS fragmentation. The relative 
configuration was elucidated by J value and NOESY correlation, however, it was 
necessary to conduct Mosher method or X-ray crystallography to determine the 
absolute configuration. In the case of diacyl angular dihydropyranocoumarin, partial 
hydrolysis was carried out to obtain a free 4’-OH prior to the Mosher method.  
In addition, CD and ECD calculation could be applied to determine the absolute 
configuration, if these coumarins could not make single crystal. If the khellactone 
ester exhibited a negative first Cotton effect at 318-329 nm, a NOESY correlation 
between 3’ and 4’ protons, and J value (4.6 ~ 5.0 Hz) between 3’ and 4’ protons, the 
absolute configuration could be suggested as 3’(S) and 4’(S) regardless of the 
presence of the 3’- or 4’-substituents.  
The enantiomers could exist in these angular dihydropyranocoumarins, and be 
isolated using chiral-selective column. Because the ratios of the major and minor 
MTPA reaction products and enantioseparation products were similar, HPLC 
analysis of MTPA reaction products could be applied to detect the enantiomers. 
In the case of monoacylkhellactone, 3’- and 4’- substituents could be interconverted 
and the equilibrium was reached about 4 days after purification. Because of acyl 
migration, 3’- and 4’- positional isomers might be isolated together.. 
The major MS fragment peak of khellactone ester was observed without a 4’-ester 




Therefore, the position of 3’- and 4’-substituents could be suggested in consideration 
of the MS fragmentation. 
Among the isolated compounds, the NO production inhibitory activity was tested 
in LPS-induced RAW264.7 cells. As a result, compounds 1, 3-6, 22, 31, and 36-38 
exhibited significant inhibitory activity without cytotoxicity. Based on the structure-
activity relationship, it was revealed that the presence of isobutyryl, senecioyl, 2-
methylbutyryl, and isovaleryl groups at 3’ position was important for the activity 
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식방풍 (Peucedani Japonici Radix) 은 미나리과 (Umbelliferae) 에 속하는 
갯기름나물 (Peucedanum japonicum Thunberg) 의 뿌리이다. 갯기름나물은 
남부와 동부 아시아 국가들에 널리 분포되어 있으며, 식방풍은 한국과 
대만 등지에서 전통적으로 감기나 통증을 치료하는데 사용되어 왔다. 
식방풍에서는 coumarin, chromone, polyacetylene, sugar alcohol, steroid 
glycoside 등이 분리 보고되었으며, 이중에서 coumarin이 대표성분으로 
알려져 있다. 식방풍의 활성으로는 항산화, 항염증, 항균작용과 
림프성백혈병세포에 대한 세포독성효과가 보고된 바 있다. 
본 연구에서는, 식방풍의 헥산과 클로로포름 분획물로부터 총 64종의 
화합물이 분리되었고, 그 중 19종의 신규화합물은 angular dihydropyrano 
coumarins (1-16) 와 angular monohydro-monohydroxy-furano coumarins (41-43) 
로, 각각 (3’S,4’S)-3'-O-isobutyryl-4'-O-(2-methylbutyryl)khellactone (1), 
(3’S,4’S)-3'-O-acetyl-4'-O-senecioylkhellactone (2), (3’S,4’S)-4'-O-isobutyryl-3'-O-
(2-methylbutyryl)khellactone (3), (3’S,4’S)-3'-O-(2-methylbutyryl)-4'-O-senecioyl 
khellactone (4), (3’S,4’S)-4'-O-(2-methylbutyryl)-3'-O-senecioylkhellactone (5), 
(3’S,4’S)-3'-O-isobutyryl-4'-O-isovaleryl khellactone (6), (3’S,4’S)-4'-O-angeloyl-
3'-O-(2-methylbutyryl)khellactone (7), (3’S,4’S)-3'-O-butyryl-4'-O-(2-methyl 
butyryl)khellactone (8), (3’S,4’S)-4'-O-angeloyl-3'-O-isovalerylkhellactone (9), 
(3’S,4’S)-3'-O-acetyl-4'-O-(3-hydroxyisovaleryl)khellactone (10), (3’S,4’S)-3'-O-
acetyl-4'-O-(3-hydroxy-2-methylbutyryl)khellactone (11), (3’S,4’S)-3'-O-acetyl-4'-
O-(2-methylbutyryl)khellactone (12), (3’S,4’S)-3'-O-(2-methylbutyryl)khellactone 
(13), (3’S,4’S)-4'-O-(2-methylbutyryl)khellactone (14), (3’S,4’S)-4'-O-methyl-3'-O-
(2-methylbutyryl)khellactone (15), (3’S,4’R)-4'-O-senecioylkhellactone (16), 2’-
hydroxy-3’-O-senecioylvaginol (41), 2’-hydroxy-3’-O-(2-methylbutyryl)vaginol 
(42), 2’-hydroxy-3’-O-isovalerylvaginol (43) 로 명명하였다. 분리된 기지화합
물들의 구조는 angular dihydropyranocoumarins (17-40), linear furanocoumarins 




simple coumarins (50-58), chromone (59), ferulic acid derivatives (60-61), lignan 
(62), phenylpropanoid (63), indole alkaloid (64) 로 규명되었다.  
분리된 화합물 중 angular dihydropyranocoumarins (khellactones) 가 
대부분을 차지하는데, 이것은 monoacyl기를 가진 형태와 diacyl기를 가진 
형태 두 가지가 있다. Monoacylkhellactones의 경우에는 MTPA 반응을 
통해 절대구조를 결정할 수 있지만, diacylkhellactones의 경우에는 
수산기의 부재로 인하여 입체구조를 밝히는 것이 매우 어렵다. 따라서 
본 연구에서는 부분 가수분해를 통하여 4’위치의 치환기를 제거 후 
Mosher method를 사용하거나 X선 회절분석법을 통하여 3’과 4’위치의 
절대구조를 결정하였다. 그러나 부분 가수분해와 단결정 생성은 
성공률이 매우 낮기 때문에 나머지 구조들을 이용하여 ECD 측정과 
계산을 통해 입체구조를 결정하는 방법 또한 제시하였다. 
분리과정 중, 거울상 이성질체의 존재를 확인하였으며 카이랄 컬럼을 
이용하여 분리하였다. 거울상 이성질체의 검출과 분리는 카이랄 
컬럼으로 하는 것이 가장 이상적이지만 분리할 화합물에 적합한 컬럼을 
찾는 것이 어렵고 컬럼이 고가라는 단점이 있다. 따라서, 거울상 
이성질체 혼합물의 MTPA 유도체를 역상 HPLC 컬럼으로 분석해도 
카이랄 컬럼으로 분석했을 때와 유사한 분리능을 갖는다는 점을 통해 
손쉬운 거울상 이성질체의 확인방법을 제시하였다. 이외에도 cis형태의 
monoacylkhellactones의 경우 3’과 4’위치에서 acyl기의 상호전환이 
나타나서 3’과 4’의 위치이성질체가 모두 나타나는 현상도 발견했다. 
또한, MS를 측정하였을 때, 4’위치의 치환기가 3’위치의 치환기보다 
우세하게 이탈하는 fragmentation을 관찰하여 HMBC의 측정없이도 3’과 
4’위치의 치환기를 연결하는 방법 또한 확인되었다.   
분리된 화합물을 대상으로 LPS로 유도한 RAW264.7 세포주에 대해 
NO 생성 저해능을 평가하였다. 화합물 중 1, 3-6, 22, 31, 36-38가 강한 
NO생성 저해능을 나타내었다.  




제시하였다. 이러한 방법들은 유사한 구조의 입체구조를 결정하는데 
있어 유용한 길잡이가 될 것으로 전망된다. 또한 분리된 화합물들을 
염증성 질환 약물 개발에 후보물질로 발전시킬 가능성도 기대된다. 
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